Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
The mission of the Cambridge Stem Cell Institute (CSCI) is to transform the prevention, diagnosis and treatment of disease through a deep understanding of the mechanisms regulating normal and pathological stem cells. Outstanding research scientists, technology specialists and doctors work side-by-side in a world-leading centre of excellence. In 2018 all the members of CSCI, currently based at several sites across the University, will come together in a purpose-built building situated in the heart of the University’s Biomedical Campus.
Together, we will apply pioneering methods and technologies to respond to three
driving questions:
• How do normal stem cells behave in healthy tissues?
• How do abnormal stem cells contribute to disease?
• How can we use this knowledge to deliver stem cell based treatments?
Together, we will apply pioneering methods and technologies to respond to three
driving questions:
• How do normal stem cells behave in healthy tissues?
• How do abnormal stem cells contribute to disease?
• How can we use this knowledge to deliver stem cell based treatments?
Technical Summary
Stem and progenitor cells are essential for the maintenance of metazoan tissues. Their dysfunction underlies diverse human diseases and their manipulation provides enormous therapeutic possibilities. The Cambridge Stem Cell Institute (CSCI) is a world-leading centre for stem cell research. Its mission is to transform the prevention, diagnosis and treatment of disease through a deep understanding of the mechanisms regulating stem and progenitor cells, both normal and pathological.
In 2018 CSCI investigators will come together in a new purpose-built building on the Cambridge Biomedical Campus adjacent to Addenbrookes Hospital. A key strategy is to embed biological, clinical and physical scientists operating across disparate tissues and at multiple scales, thus allowing commonalities and differences to be explored in an cohesive and inter-disciplinary manner. A network of affiliated PIs will provide bridges to basic and disease-focused institutes throughout Cambridge and will ensure that CSCI represents the heart of a vibrant stem cell community. Importantly a critical mass of clinician scientists will create synergistic interactions between basic scientists and those driven by disease-focused questions, thus ensuring that CSCI is fully integrated with its clinical environment and empowered to pursue its translational goals.
In 2018 CSCI investigators will come together in a new purpose-built building on the Cambridge Biomedical Campus adjacent to Addenbrookes Hospital. A key strategy is to embed biological, clinical and physical scientists operating across disparate tissues and at multiple scales, thus allowing commonalities and differences to be explored in an cohesive and inter-disciplinary manner. A network of affiliated PIs will provide bridges to basic and disease-focused institutes throughout Cambridge and will ensure that CSCI represents the heart of a vibrant stem cell community. Importantly a critical mass of clinician scientists will create synergistic interactions between basic scientists and those driven by disease-focused questions, thus ensuring that CSCI is fully integrated with its clinical environment and empowered to pursue its translational goals.
Organisations
- University of Cambridge (Lead Research Organisation)
- University of Oslo (Collaboration)
- California Institute of Technology (Collaboration)
- LOUGHBOROUGH UNIVERSITY (Collaboration)
- Cambridge Design Partnership (Collaboration)
- Novo Nordisk (Collaboration)
- University of Navarra Clinic (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Centre for Genomic Regulation (CRG) (Collaboration)
- University of Vienna (Collaboration)
- Max Planck Society (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- University of Sheffield (Collaboration)
- University Medical Center Freiburg (Collaboration)
- IRCCS Policlinico San Donato (Collaboration)
- Sysmex Corporation (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- Bit.Bio (Collaboration)
- University of Bristol (Collaboration)
- Francis Crick Institute (Collaboration)
- University College London (Collaboration)
- University of Manchester (Collaboration)
- University of Kumamoto (Collaboration)
- Abcam (Collaboration)
- Washington University in St. Louis (Collaboration)
- Babraham Institute (Collaboration)
- University of Dundee (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Altos Labs (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- Bayer (Collaboration)
- University of Tokyo (Collaboration)
- Swiss Federal Institute of Technology in Lausanne (EPFL) (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- National University of Singapore (Collaboration)
- University of California, Davis (Collaboration)
- Lund University (Collaboration)
- UNIVERSITY OF YORK (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- University of Washington (Collaboration)
People |
ORCID iD |
Publications
Brevini T
(2023)
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
in Nature
Brevini T
(2020)
Tissue engineering of the biliary tract and modelling of cholestatic disorders.
in Journal of hepatology
Bruzelius A
(2021)
Reprogramming Human Adult Fibroblasts into GABAergic Interneurons.
in Cells
Buecker C
(2021)
Science shines in a new virtual SY-Stem
in Development
Bulley SJ
(2022)
Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study.
in EJHaem
Burgos JI
(2021)
Monogenic Diabetes Modeling: In Vitro Pancreatic Differentiation From Human Pluripotent Stem Cells Gains Momentum.
in Frontiers in endocrinology
Burnett AK
(2021)
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
in Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Burrows N
(2020)
Dynamic regulation of hypoxia-inducible factor-1a activity is essential for normal B cell development.
in Nature immunology
| Title | A Pattern for Progress (2019) by Harold Offeh |
| Description | Harold Offeh brought together people living with multiple sclerosis (MS) and their carers, with scientists researching this neurological disease. Through a series of ceramic workshops, participants shared their experiences of MS and produced the tiles converted into a vinyl 'wallpaper' by the artist. An accompanying film captures their stories. Commissioned by the Wellcome-MRC Cambridge Stem Cell Institute Public Engagement programme, in partnership with the MS Society and Kettle's Yard. |
| Type Of Art | Artwork |
| Year Produced | 2019 |
| Impact | Non known |
| URL | https://www.haroldoffeh.com/projects/a-pattern-for-progress |
| Title | Let The Eye Be Substituted For The Sun (2019) by Victoria Morton |
| Description | This work was created through time spent in laboratories talking to scientists about their research. The artist was fascinated by the technology used to cultivate and visualise cells at the microscopic level, and hopes the artwork reflects these complex processes, whilst allowing the mind to wander and focus at the same time. Commissioned by the Wellcome-MRC Cambridge Stem Cell Institute Public Engagement programme for the Jeffrey Cheah Biomedical Centre, in partnership with Kettle's Yard. |
| Type Of Art | Artwork |
| Year Produced | 2019 |
| Impact | None known |
| URL | https://www.stemcells.cam.ac.uk/about-us/jcbc/art/victoria-morton |
| Title | The Night the Mountains Moved (2020) and Futuramic Unknown (2020) by Anna Brownsted |
| Description | Anna Brownsted created this work in response to a project connecting Blood Cancer UK patient ambassadors and stem cell researchers. Together, they explored experiences of 'the unknown' in living with blood cancer, the challenges of research, and the Covid-19 pandemic. The artist drew inspiration for this collage from animations created by project participants using photographs from National Geographic published in 1960 - the year Blood Cancer UK was founded - and compiled in the accompanying film Futuramic Unknown. Commissioned by the Wellcome-MRC Cambridge Stem Cell Institute Public Engagement programme, in partnership with Blood Cancer UK and Kettle's Yard. |
| Type Of Art | Artwork |
| Year Produced | 2020 |
| Impact | Not known |
| URL | https://www.annabrownsted.com/the-night-the-mountains-moved-https%3A/www.stemcells.cam.ac.uk/about-u... |
| Description | (ChRONAM-H) - Chromatin Regulation Of Normal And Malignant Haematopoiesis |
| Amount | € 212,934 (EUR) |
| Funding ID | 886474 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2020 |
| End | 09/2022 |
| Description | (HARMONY PLUS) - HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY - PLUS |
| Amount | € 11,882,669 (EUR) |
| Funding ID | 945406 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2020 |
| End | 09/2023 |
| Description | (NSC-Reconstruct) - Novel Strategies for Cell-based Neural Reconstruction |
| Amount | € 8,169,231 (EUR) |
| Funding ID | 874758 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2020 |
| End | 12/2023 |
| Description | 21EBTA. Bioengineering iLUNGs - Building scalable, integrated, multicellular and personalised human in vitro LUNGs |
| Amount | £1,307,548 (GBP) |
| Funding ID | BB/W014564/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2024 |
| Description | BLACK INTERNS PROGRAMME SUMMER 2022 |
| Amount | £8,600 (GBP) |
| Organisation | Genome Research Ltd |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2022 |
| End | 10/2022 |
| Description | BRAINS FOR DEMENTIA RESEARCH STEM CELL AND FIBROBLAST RESOURCE |
| Amount | £50,000 (GBP) |
| Organisation | Newcastle University |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2020 |
| End | 09/2022 |
| Description | Bioengineering The iLUNGs BBSRC |
| Amount | £193,789 (GBP) |
| Funding ID | BB/W014564/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2024 |
| Description | Biogenesis and bioengineering of human platelets |
| Amount | £593,451 (GBP) |
| Funding ID | 219472/A/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 02/2025 |
| Description | Bridging Funds support |
| Amount | £96,856 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 03/2023 |
| Description | CHARACTERISATION OF ENHANCER RNA EXPRESSION AND |
| Amount | £162,585 (GBP) |
| Organisation | Sysmex Corporation |
| Sector | Private |
| Country | Japan |
| Start | 04/2022 |
| End | 03/2024 |
| Description | CHARACTERISING THE ROLE OF TRANSLATED MICROPEPTIDES IN DIFFU |
| Amount | £9,931 (GBP) |
| Funding ID | Seedcorn2020\100305 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 03/2022 |
| Description | CHARACTERISING THE ROLE OF TRANSLATED MICROPEPTIDES IN DIFFUSE LARGE B-CELL LYMPHOMA |
| Amount | £19,628 (GBP) |
| Funding ID | 35585 |
| Organisation | British Society for Haematology |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 10/2022 |
| Description | CHARACTERISING THE ROLE OF TRANSLATED MICROPEPTIDES IN DIFFUSE LARGE B-CELL LYMPHOMA |
| Amount | £19,628 (GBP) |
| Organisation | British Society for Haematology |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 03/2022 |
| Description | CHROMATIN (MIS) REGULATION OF LINEAGE COMMITMENT IN LEUKEMIA |
| Amount | £129,310 (GBP) |
| Funding ID | GENE REGULATORY COMPLEXES AND NETWORKS REGULATED BY THE ERG |
| Organisation | European Hematology Association (EHA) |
| Sector | Charity/Non Profit |
| Country | Netherlands |
| Start | 10/2021 |
| End | 09/2024 |
| Description | COLLABORATION: ASTRAZENECA UK LIMITED - ELUCIDATING NON-GENE |
| Amount | £378,785 (GBP) |
| Funding ID | 10046922 |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 08/2023 |
| Description | COLLABORATION: ASTRAZENECA UK LTD - THE MOLECULAR PATHOGENES |
| Amount | £379,164 (GBP) |
| Funding ID | 10047580 |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 03/2024 |
| Description | COLLABORATION: GENOME RESEARCH LIMITED - DECIPHERING MYELOID |
| Amount | £494,925 (GBP) |
| Funding ID | 10115 |
| Organisation | Genome Research Ltd |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2020 |
| End | 04/2024 |
| Description | COLLABORATION: GENOME RESEARCH LIMITED - IMMUNO-ONCOLOGY TAR |
| Amount | £50,000 (GBP) |
| Organisation | Genome Research Ltd |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 04/2024 |
| Description | COLLABORATION: NADACE AGING BIOLOGY FOUNDATION EUROPE - SING |
| Amount | £52,779 (GBP) |
| Funding ID | Single cell profiling of open chromatin status in human bone marrow mononuclear cells from young and old donors". |
| Organisation | Aging Biology Foundation Europe |
| Sector | Private |
| Country | Czech Republic |
| Start | 04/2022 |
| End | 03/2023 |
| Description | COLLABORATION: NADACE AGING BIOLOGY FOUNDATION EUROPE - SING |
| Amount | £52,779 (GBP) |
| Organisation | Aging Biology Foundation Europe |
| Sector | Private |
| Country | Czech Republic |
| Start | 04/2022 |
| End | 03/2023 |
| Description | COLLABORATION: UNIVERSITY OF NEWCASTLE UPON TYNE (/FB ALZHEI |
| Amount | £500,000 (GBP) |
| Organisation | Newcastle University |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2020 |
| End | 09/2022 |
| Description | COLLABORATION: UNIVERSITY OF YORK (FB MRC) - HUMAN BLOOD STE |
| Amount | £634,916 (GBP) |
| Funding ID | MR/V005502/1 |
| Organisation | University of York |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 09/2023 |
| Description | COLLABORATION: WEIZMANN INSTITUTE OF SCIENCE - CIRCADIAN RHY |
| Amount | £36,837 (GBP) |
| Funding ID | COLLABORATION: WEIZMANN INSTITUTE OF SCIENCE - CIRCADIAN RHY |
| Organisation | American Committee for the Weizmann Institute of Science |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 10/2020 |
| End | 09/2022 |
| Description | COMBATTING PROGRESSION IN MS - WHEN AND HOW? |
| Amount | £1,850,000 (GBP) |
| Funding ID | 132 |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 03/2025 |
| Description | CONSORTIUM: H2020 IMI2 - HEALTHCARE ALLIANCE FOR RESOURCEFUL |
| Amount | £80,357 (GBP) |
| Funding ID | 945406 |
| Organisation | IMI Europe Limited |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 09/2023 |
| Description | CRE BHF |
| Amount | £13,800 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 07/2022 |
| Description | Cambridge Stem Cell Institute |
| Amount | £3,286,966 (GBP) |
| Funding ID | 203151/A/16/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 06/2024 |
| Description | Cell fate regulation during gastrulation in humans and pigs |
| Amount | £79,145 (GBP) |
| Funding ID | BB/S001816/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 12/2022 |
| Description | Cellular and molecular characterisation of epithelial tumour initiation |
| Amount | £1,613,965 (GBP) |
| Funding ID | DCRPGF\100010 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 02/2027 |
| Description | DECIPHERING THE GENOMICS OF AGGRESSIVE NON-HODGKIN LYMPHOMA |
| Amount | £2,142,349 (GBP) |
| Funding ID | RCCFEL\100072 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 03/2027 |
| Description | DECIPHERING THE MECHANISMS OF EPIGENETIC |
| Amount | £300,000 (GBP) |
| Funding ID | 222800 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2021 |
| End | 06/2025 |
| Description | DEVELOPING CELL MODELS TO INTERROGATE MECHANICAL SIGNALLING |
| Amount | £24,216 (GBP) |
| Funding ID | 21.07(d) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 01/2022 |
| Description | DRUGGING A CORE TRANSCRIPTIONAL PROGRAMME HIJACKED BY ALL GE |
| Amount | £249,789 (GBP) |
| Organisation | Blood Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 07/2025 |
| Description | Defective clearance of innate immune neutrophils as a potential cause and therapeutic target in myeloproliferative neoplasms with high risk of leukaemic transformation |
| Amount | £150,000 (GBP) |
| Funding ID | 2022/JGF/002 |
| Organisation | Leukaemia UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2022 |
| End | 10/2024 |
| Description | Developing Early Intervention Strategies for High-Risk Clonal Hematopoiesis |
| Amount | £489,099 (GBP) |
| Funding ID | EDDAMC-2021\100010 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 06/2025 |
| Description | Exploiting stage-specific dependencies on RNA helicases in MYC-driven lymphoma" |
| Amount | £264,618 (GBP) |
| Funding ID | KKL1398 |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2021 |
| End | 04/2024 |
| Description | FIRST STEPS TOWARDS CHEMOTHERAPY-FREE TREATMENT OF SGK1-MUTA |
| Amount | £227,078 (GBP) |
| Funding ID | KKL1445 |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 04/2023 |
| Description | FIRST STEPS TOWARDS CHEMOTHERAPY-FREE TREATMENT OF SGK1-MUTA |
| Amount | £73,842 (GBP) |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 04/2023 |
| Description | GENE REGULATORY COMPLEXES AND NETWORKS REGULATED BY THE ERG |
| Amount | £35,000 (GBP) |
| Funding ID | LT100 |
| Organisation | Lady Tata Memorial Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 09/2021 |
| Description | GENE REGULATORY COMPLEXES AND NETWORKS REGULATED BY THE ERG |
| Amount | £88,503 (GBP) |
| Funding ID | CHROMATIN (MIS) REGULATION OF LINEAGE COMMITMENT IN LEUKEMIA |
| Organisation | European Hematology Association (EHA) |
| Sector | Charity/Non Profit |
| Country | Netherlands |
| Start | 10/2020 |
| End | 09/2022 |
| Description | GENE REGULATORY NETWORKS IN NORMAL AND MALIGNANT HEMATOPOIES |
| Amount | £248,508 (GBP) |
| Funding ID | HR20-00871 |
| Organisation | University of Navarra |
| Sector | Academic/University |
| Country | Spain |
| Start | 12/2020 |
| End | 11/2023 |
| Description | GENERATING A GLOBAL VIEW OF CELL LINEAGE TREES DURING EARLY |
| Amount | £300,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2020 |
| End | 03/2023 |
| Description | GENERATION OF TISSUE-RESIDENT CARDIAC MACROPHAGES FROM HUMAN |
| Amount | £9,500 (GBP) |
| Funding ID | 111882 |
| Organisation | ACT |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 03/2021 |
| End | 02/2022 |
| Description | Generating platelets in vitro for the clinic: optimisation and added clinical efficacy |
| Amount | £474,809 (GBP) |
| Funding ID | MR/V005413/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2023 |
| Description | HE ROLE OF A COMMON FACTOR V HAPLOTYPE IN PROTECTING |
| Amount | £19,775 (GBP) |
| Organisation | British Society for Haematology |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2021 |
| End | 09/2022 |
| Description | Human Cell Atlas - development atlas extension |
| Amount | £119,697 (GBP) |
| Funding ID | 221052/C/20/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 11/2022 |
| Description | IDENTIFICATION AND FUNCTIONAL CHARACTERISATION OF CORE METAB |
| Amount | £244,219 (GBP) |
| Funding ID | KKL1440 |
| Organisation | The Kay Kendall Leukaemia Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 06/2023 |
| Description | INVESTIGATION OF GENETIC VULNERABILITIES OF DNMT3A-MUTANT PR |
| Amount | £248,683 (GBP) |
| Funding ID | 21006 |
| Organisation | Blood Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2021 |
| End | 12/2023 |
| Description | Identifying novel drug combinations in B-Acute Lymphoblastic Leukaemia by iterative functional genomics screening |
| Amount | £149,993 (GBP) |
| Funding ID | 2022/JGF/004 |
| Organisation | Leukaemia UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2022 |
| End | 09/2024 |
| Description | Impact of tissue mechanics on epithelial and mesenchymal cross-talk; relevance for tissue regeneration. |
| Amount | £818,932 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2025 |
| Description | Improving haematopoietic reconstitution in blood stem cell transplantation |
| Amount | £634,921 (GBP) |
| Funding ID | MR/V005421/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 09/2023 |
| Description | Improving haematopoietic reconstitution in blood stem cell transplantation procedures through the regulation of stem cells and their niches |
| Amount | £634,921 (GBP) |
| Funding ID | MR/V005421/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2023 |
| Description | Initiation of the first heartbeat; from single cell calcium oscillations to propagating waves |
| Amount | £267,013 (GBP) |
| Funding ID | FS/18/24/33424 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 04/2023 |
| Description | Junior Research Grant |
| Amount | € 100,000 (EUR) |
| Funding ID | RG65 |
| Organisation | European Hematology Association (EHA) |
| Sector | Charity/Non Profit |
| Country | Netherlands |
| Start | 10/2020 |
| End | 09/2022 |
| Description | KING'S COLLEGE FELLOW - DR MYFANWY HILL |
| Amount | £250,000 (GBP) |
| Funding ID | Loke Fellowship |
| Organisation | King's College |
| Sector | Academic/University |
| Country | United States |
| Start | 01/2021 |
| End | 12/2025 |
| Description | MECHANOMODULATION OF MUTANT CLONAL COMPETITION IN OESOPHAGEA |
| Amount | £25,300 (GBP) |
| Funding ID | 117877 |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 06/2023 |
| Description | MINUTE 21.39(B) NICHE-DEPENDENCIES AND DRUG RESISTANCE IN B |
| Amount | £21,154 (GBP) |
| Funding ID | MINUTE 21.39(B) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 12/2022 |
| Description | MINUTE 21.39(B) NICHE-DEPENDENCIES AND DRUG RESISTANCE IN B |
| Amount | £21,154 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 12/2022 |
| Description | MOLECULAR BASIS OF ABNORMAL EXCITATORY-INHIBITORY NEURONAL I |
| Amount | £69,667 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 09/2023 |
| Description | Mechanisms of adhesion-dependent haematopoietic transdetermination |
| Amount | £575,124 (GBP) |
| Funding ID | MR/T028343/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2020 |
| End | 07/2023 |
| Description | Microenvironment Regulation of Zika Virus Susceptibility in Human Brain Development and Malignant Glioma |
| Amount | £861,960 (GBP) |
| Funding ID | 223011 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2022 |
| End | 04/2026 |
| Description | Microenvironment Regulation of Zika Virus Susceptibility in Human Brain Development and Malignant Glioma |
| Amount | £861,960 (GBP) |
| Funding ID | 223011/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2022 |
| End | 04/2026 |
| Description | Molecular mechanisms of cell fate decisions in gastrulation and early organogenesis |
| Amount | £2,379,992 (GBP) |
| Funding ID | 220379/B/20/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 11/2025 |
| Description | NAILING REGENERATION: INVESTIGATING THE ROLE OF THE NAIL IN |
| Amount | £20,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 03/2023 |
| Description | Newton Trust MS - In Full Force: Investigating the mechanica |
| Amount | £65,770 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 06/2024 |
| Description | Newton Trust MS - In Full Force: Investigating the mechanica |
| Amount | £65,770 (GBP) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 06/2024 |
| Description | Patterning the embryo, one signalling |
| Amount | £300,000 (GBP) |
| Funding ID | 224070 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 02/2026 |
| Description | Patterning the embryo, one signalling molecule at a time |
| Amount | £300,000 (GBP) |
| Funding ID | 224070/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 02/2026 |
| Description | REGENERATIVE MEDICINE APPLICATIONS OF CHOLANGIOCYTE ORGANOID |
| Amount | £1,530,439 (GBP) |
| Funding ID | MR/V023004/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 09/2025 |
| Description | RESEARCH MOBILITY GRANT FOR AINHOA GONI |
| Amount | £3,211 (GBP) |
| Organisation | European Hematology Association (EHA) |
| Sector | Charity/Non Profit |
| Country | Netherlands |
| Start | 05/2022 |
| End | 07/2022 |
| Description | ROLE OF MECHANICAL SIGNALLING AT THE NUCLEAR ENVELOPE IN PLU |
| Amount | £645,393 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 09/2024 |
| Description | ROLE OF MECHANICAL SIGNALLING AT THE NUCLEAR ENVELOPE IN PLU |
| Amount | £431,138 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 12/2024 |
| Description | ROSETREES TRUST - HUMAN ORGANOID MODELLING OF NEUROGENETIC E |
| Amount | £37,500 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 09/2024 |
| Description | Role of mechanical signalling at the nuclear envelope in pluripotent stem cell differentiation |
| Amount | £645,392 (GBP) |
| Funding ID | BB/W000423/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2024 |
| Description | SINGLE-CELL ANALYSIS DISSECTS CLONAL SPECIFIC CHROMATIN STAT |
| Amount | £740,000 (GBP) |
| Funding ID | NAFR12_1011 |
| Organisation | Academy of Medical Sciences (AMS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2023 |
| Description | STROMAL NICHE ORCHESTRATES EPITHELIAL CELL BEHAVIOUR IN EARL |
| Amount | £23,571 (GBP) |
| Funding ID | 21.07(a) |
| Organisation | University of Cambridge |
| Department | Isaac Newton Trust |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 04/2022 |
| Description | Structural studies of the ATRX-DAXX chromatin remodeller complex and its role in heterochromatin and telomere maintenance |
| Amount | £379,655 (GBP) |
| Funding ID | 223008 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 01/2026 |
| Description | Structural studies of the ATRX-DAXX chromatin remodeller complex and its role in heterochromatin and telomere maintenance |
| Amount | £379,655 (GBP) |
| Funding ID | 223008/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 01/2026 |
| Description | TARGETING THE BONE MARROW ENDOTHELIAL NICHE TO IMPROVE THERA |
| Amount | £249,149 (GBP) |
| Organisation | Blood Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 03/2025 |
| Description | TBC |
| Amount | £19,480 (GBP) |
| Funding ID | 106325 |
| Organisation | The Evelyn Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 01/2022 |
| Description | THE MECHANICS OF OESOPHAGEAL TUMOUR FORMATION |
| Amount | £20,000 (GBP) |
| Funding ID | RGS\R1\211424 |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2022 |
| Description | TOWARDS AN EARLY DETECTION PROGRAMME FOR MYELOID MALIGNANCIE |
| Amount | £665,791 (GBP) |
| Funding ID | EDDCPJT\100010 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 08/2025 |
| Description | Targeting remodelling of lung stem and niche cells: lessons from regeneration to disease |
| Amount | £2,107,440 (GBP) |
| Funding ID | 221857 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2021 |
| End | 06/2026 |
| Description | The cellular immune response to B.1.1.7 variant COVID-19 deciphered by single cell |
| Amount | £37,300 (GBP) |
| Funding ID | MR/W014556/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 07/2021 |
| Description | UK Human Developmental Biology Initiative |
| Amount | £133,303 (GBP) |
| Funding ID | 215116/A/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 09/2024 |
| Description | UPSCALED HEPATOCYTE CULTURE FOR LIVER CELL THERAPY |
| Amount | £42,841 (GBP) |
| Organisation | The Evelyn Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2021 |
| End | 10/2022 |
| Description | Understanding of metabolic and acetyl state in hPSC for large scale production |
| Amount | £103,929 (GBP) |
| Funding ID | BB/W510385/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2025 |
| Description | University of Sheffield (f/b Cystic Fibrosis Trust) |
| Amount | £20,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 12/2026 |
| Description | Unravelling the whipworm niche at the host intestinal epithelia |
| Amount | £1,176,163 (GBP) |
| Funding ID | 222546/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2021 |
| End | 01/2027 |
| Description | Wellcome Four Year PhD Programme in Stem Cell Biology and Medicine |
| Amount | £6,051,821 (GBP) |
| Funding ID | 218481/Z/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 09/2028 |
| Description | Ana Cvejic - EBI |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ana Cvejic - Collaborative project |
| Collaborator Contribution | Collaborative research with Moritz Gerstung of the EMBL European Bioinformatics Institute. |
| Impact | Outputs expected |
| Start Year | 2020 |
| Description | Ana Cvejic - Wellcome Sanger Institute |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | CSCI PI Ana Cvejic - Collaborative project |
| Collaborator Contribution | Collaboration with Omer Ali Bayraktar at the Wellcome Trust Sanger Institute. |
| Impact | Outputs expected |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Dundee |
| Organisation | University of Dundee |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Greg Findlay of the University of Dundee |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Edinburgh |
| Organisation | University of Edinburgh |
| Department | Centre for Discovery Brain Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with John Mason of the University of Edinburgh's Centre for Discovery Brain Sciences. |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - University of Oslo |
| Organisation | University of Oslo |
| Department | Institute of Basic Medical Sciences |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Gareth Sullivan of the University of Oslo's Institute of Basic Medical Sciences. |
| Impact | Grant application outcome unknown |
| Start Year | 2020 |
| Description | Brian Hendrich - Washington University in St. Louis |
| Organisation | Washington University in St Louis |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Hendrich - joint grant application |
| Collaborator Contribution | Joint grant application with Sabine Dietman of the Washington University (St Louis) School of Medicine. |
| Impact | Application outcome unknown |
| Start Year | 2020 |
| Description | Brian Huntly - Babraham Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaborative project with Wolf Reik of Babraham Institute's Epigenetics lab. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - Centre for Genomic Regulation |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaboration with Marc Marti-Renom of the Centre for Genomic Regulation |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - Institut Gustave Roussy |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project |
| Collaborator Contribution | Collaboration with Thomas Mercher of l'Institut Gustave Roussy |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Brian Huntly - University of Navarra |
| Organisation | University of Navarra Clinic |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | CSCI PI Brian Huntly - Collaborative project and joint grant application |
| Collaborator Contribution | Collaboration and joint grant application with Felipe Prosper of University of Navarra Clinic. |
| Impact | Outcomes expected later in 2021 |
| Start Year | 2020 |
| Description | Brian Huntly's collaboration with Sysmex Corporation 'Characterisation of enhancer RNA expression and function in acute myeloid leukaemia' |
| Organisation | Sysmex Corporation |
| Country | Japan |
| Sector | Private |
| PI Contribution | Using the CAGE and SLIC-CAGE techniques developed by Sysmex to characterise enhancer RNA expression and function in acute myeloid leukaemia |
| Collaborator Contribution | Sharing of the CAGE and SLIC-CAGE techniques developed by Sysmex |
| Impact | Too early for outcomes. Publication expected 2024-25. |
| Start Year | 2022 |
| Description | CSCI PI , Collaborative project - Myelin Plasticity in learning |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Knowledge Transfer |
| Collaborator Contribution | Knowledge Transfer |
| Impact | Knowledge of behavioural experiments and co-written paper to Science Papers written below 1. Bonetto G, Belin D, Káradóttir RT. (2021) Myelin: A gatekeeper of activity-dependent circuit plasticity? Science 2;374(6569) 2. Belin D & Káradóttir RT (2016). Writing a constructive peer-review: a young PI per-spective. European Journal of Neuroscience 44(11): 2873-2876. This paper has been shared and discussed greatly on social media, in the top 5% of outputs tracked by Al-metric. |
| Start Year | 2022 |
| Description | CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Project leadership. Design of new murine models of myeloid and malignancy. |
| Collaborator Contribution | Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models |
| Impact | Mouse models are still in development. |
| Start Year | 2022 |
| Description | CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis |
| Organisation | Medical Research Council (MRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Project leadership. Design of new murine models of myeloid and malignancy. |
| Collaborator Contribution | Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models |
| Impact | Mouse models are still in development. |
| Start Year | 2022 |
| Description | CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Project leadership. Design of new murine models of myeloid and malignancy. |
| Collaborator Contribution | Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models |
| Impact | Mouse models are still in development. |
| Start Year | 2022 |
| Description | CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Project leadership. Design of new murine models of myeloid and malignancy. |
| Collaborator Contribution | Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models |
| Impact | Mouse models are still in development. |
| Start Year | 2022 |
| Description | CSCI PI Brian Huntley. - Novel tools for modelling normal and perturbed haematosis |
| Organisation | University of York |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Project leadership. Design of new murine models of myeloid and malignancy. |
| Collaborator Contribution | Project leadership. Design of new murine models of myeloid and malignancy and developmental haematopoiesis. Creation of models |
| Impact | Mouse models are still in development. |
| Start Year | 2022 |
| Description | CSCI PI Dan Hodson - Collaborative project |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Collaboration with Andrew Mortlock at AstraZeneca Cambridge involving the DIRECT Trial - a molecular profiling study in aggressive B cell lymphoma |
| Collaborator Contribution | . |
| Impact | . |
| Start Year | 2020 |
| Description | CSCI PI Dan Hodson, Collaborative project - Mediators of B cell receptor expression and sensitivity of BCR-targeted drugs. |
| Organisation | National Institutes of Health (NIH) |
| Department | National Cancer Institute (NCI) |
| Country | United States |
| Sector | Public |
| PI Contribution | Performed experiments, analysed data, supervised a PhD student who worked exclusively on this project for 2 years. Contributed to manuscript writing and figure production. |
| Collaborator Contribution | Performed experiments, analysed data, supervised a PhD student who worked exclusively on this project for 2 years. Contributed to manuscript writing and figure production. |
| Impact | - Manuscript in preparation - for Cancer Discovery submission April 2023 |
| Start Year | 2018 |
| Description | CSCI PI Dan Hodson. Collaborative project - Molecular pathogenesis of double hit lymphoma |
| Organisation | National University of Singapore |
| Department | Cancer Science Institute of Singapore (CSI) |
| Country | Singapore |
| Sector | Academic/University |
| PI Contribution | Performed experiments and analysed data used in the main figures. These included cell culture and single cell RNA sequencing experiments |
| Collaborator Contribution | Performed experiments and analysed data used in the main figures. These included cell culture and single cell RNA sequencing experiments |
| Impact | Manuscript accepted at Cancer Discovery Feb 2023 |
| Start Year | 2018 |
| Description | CSCI PI Elisa Laurenti, Collaborative project. Impact of gene therapy on haematopoietic stem and progenitor cells in b-thalassemia patients |
| Organisation | IRCCS Policlinico San Donato |
| Department | San Raffaele Telethon Institute for Gene Therapy |
| Country | Italy |
| Sector | Public |
| PI Contribution | We performed scRNAseq on blood stem and progenitor cells isolated from b-thalassemia patients pre- and post- gene therapy. |
| Collaborator Contribution | Our partners provided the samples as well as their expertise on this disease. |
| Impact | Mende et al., Blood, 2022 |
| Start Year | 2020 |
| Description | CSCI PI Fotios Sampaziotis - |
| Organisation | University of Cambridge |
| Department | Cambridge Infectious Diseases |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on repurposing drug for COVID19 |
| Collaborator Contribution | Collaboration on repurposing drug for COVID19 |
| Impact | 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology |
| Start Year | 2021 |
| Description | CSCI PI Fotios Sampaziotis - |
| Organisation | University of Cambridge |
| Department | Clinical Pharmacology Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on repurposing drug for COVID19 |
| Collaborator Contribution | Collaboration on repurposing drug for COVID19 |
| Impact | 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology |
| Start Year | 2021 |
| Description | CSCI PI Fotios Sampaziotis - |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on repurposing drug for COVID19 |
| Collaborator Contribution | Collaboration on repurposing drug for COVID19 |
| Impact | 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology |
| Start Year | 2021 |
| Description | CSCI PI Fotios Sampaziotis - |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on repurposing drug for COVID19 |
| Collaborator Contribution | Collaboration on repurposing drug for COVID19 |
| Impact | 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology |
| Start Year | 2021 |
| Description | CSCI PI Fotios Sampaziotis - |
| Organisation | University of Vienna |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | Collaboration on repurposing drug for COVID19 |
| Collaborator Contribution | Collaboration on repurposing drug for COVID19 |
| Impact | 2 publications (1 in revision and uploaded on bioRxiv). Meng et al, Nature, 2020 (10.1038/s41586-022-04474-x ) Brevini et al BioRxiv, 2021 (https://doi.org/10.1101/2021.06.06.446781), In revision (Nature) Disciplines Infectious diseases, virology, transplantation surgery, hepatology, pharmacology, hepatology, gastroenterology, stem cell biology, histopathology, epidemiology, toxicology |
| Start Year | 2021 |
| Description | CSCI PI Maria Duque Correa Collaborative project - Role of Arpc1b on responses to whipworm infection |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have characterised the role of the gene Arpc1b in the immune response to Trichuris muris using KO mice and in vitro and in vivo approaches. |
| Collaborator Contribution | The partners have performed several experiments at their end and also provided us with parasite material for our own experiments. |
| Impact | Data on parasite burden, histolopathology, survival, gene expression, T cell activation for wild type and mutant mice for Arpc1b upon infection with T. muris. Manuscript in preparation. |
| Start Year | 2017 |
| Description | CSCI PI Maria Duque Correa Collaborative project - Studies on effects of Trichuris muris p43 on caecal epithelia |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have developed an in vitro system using caecal organoids that we are using in this collaboration to test the effects of p43, a protein produced by the parasite Trichuris muris. |
| Collaborator Contribution | The partners have identified and characterised p43, a protein produced by the parasite Trichuris muris. Now, we are using our organoid system to evaluate the interactions and effects of this protein (generated by the collaborators) on the intestinal epithelia. |
| Impact | Outputs, RNA-seq datasets. |
| Start Year | 2022 |
| Description | CSCI PI Maria Duque Correa Collaborative project - Study of caecal epithelia responses to whipworm infection of caecaloids |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have developed an in vitro system using caecal organoids that we are using in this to understand the intestinal epithelial responses to infection with the parasite Trichuris muris. |
| Collaborator Contribution | The partners have provided kits for single-cell sequencing and sequenced the material. Moreover, they have carried out the bioinformatic analysis for this dataset. |
| Impact | Single-cell RNA-seq dataset. |
| Start Year | 2022 |
| Description | CSCI PI Maria Duque Correa Collaborative project - Understanding the role of Isg15 in the immune response to whipworms |
| Organisation | University Medical Center Freiburg |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | I have discovered the expansion of an enterocyte population expressing Isg15 in response to whipworm infection in mice. We will evaluate the role of Isg15 by infecting knockout mice and organoids for this gene with Trichuris muris. |
| Collaborator Contribution | Provide knockout mice and antibodies |
| Impact | No outputs yet. |
| Start Year | 2022 |
| Description | CSCI PI Maria Duque Correa Collaborative project - Use of "mini-intestines" grown in scaffolds to further advance the caecaloid-whipworm model |
| Organisation | Swiss Federal Institute of Technology in Lausanne (EPFL) |
| Country | Switzerland |
| Sector | Public |
| PI Contribution | I have shared protocols, Trichuris muris eggs and caecaloids with the collaborator so he can try to reproduce the caecaloid-whipworm model using his scaffolds. |
| Collaborator Contribution | Collaborators (Prof Matthias Lutolf and Moritz Hofer) are working towards adapting the growth of caecaloids in their scaffolds so we can better reproduce the intestinal epithelia architecture and therefore, improve our model to study host-whipworm interactions. |
| Impact | Multi-disciplinary collaboration between tissue engineering, stem cell - organoid culture and parasitology. |
| Start Year | 2020 |
| Description | CSCI PI Mekayla Storer, Collaborative project - Assessing Tissue Stiffness On Regenerating Digits Using Atomic Force Microscopy" - Collaboration between Storer Lab & Kristian Franze (PDN). |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My team provides specimens to the Franze lab (this includes performing digit tip amputation surgery on mice) in order to perform atomic force microscopy to map out the relative stiffness of the regenerating digit tip. |
| Collaborator Contribution | The Franze lab performs atomic force microscopy on the samples. This includes assistance with experimental design (technical aspects of AFM), data acquisition and analyses. |
| Impact | Preliminary data resulting from the Atomic Force Microscopy was used in a recent grant application for the Wellcome Career Development Award. I was successful in this grant application. |
| Start Year | 2022 |
| Description | CSCI PI Mekayla Storer, Collaborative project - Investigating how the mechanical environment changes during bone fracture - External supervision for Graduate Student BM - Collaboration between Storer Lab & Altos Labs |
| Organisation | Altos Labs |
| Country | United States |
| Sector | Private |
| PI Contribution | Byron Mui is a PhD student who is currently undertaking his project in my laboratory. I am providing reagents, equipment/facilities and supervision of his current project that seeks to understand the role of hyaluronic acid and tissue mechanics in regulating regeneration (digit tip and fracture healing of the femur). |
| Collaborator Contribution | Kevin is a renown expert in the field of mechanobiology and provides technical/experimental expertise in conjunction with input on project design/ interpretation of the results. |
| Impact | BM's project is still in the early phases of development and has thus far, not yet generated any outputs other than preliminary data. |
| Start Year | 2022 |
| Description | CSCI PI Roger Barker - Collaborative project with Bayer |
| Organisation | Bayer |
| Country | Germany |
| Sector | Private |
| PI Contribution | Prof Barker is part of the advisory board giving them advice on how to develop their gene and cell therapies for Parkinson's Disease. He gets paid for this (about £2000 that he puts into a donation account to help support activities he does and that of my research group) but de does not do any work with them and they do not support our research in any way. |
| Collaborator Contribution | . |
| Impact | Prof Barker is part of the advisory board giving them advice on how to develop their gene and cell therapies for Parkinson's Disease. |
| Start Year | 2022 |
| Description | CSCI PI Walid Khaled - Collaborative project |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | .Collaboration with AstraZeneca involving part-time PhD studentship (AZ employee) based at Pharmacology |
| Collaborator Contribution | . |
| Impact | Collaboration with AstraZeneca involving Part-time PhD studentship (AZ employee) based at Pharmacology. |
| Start Year | 2021 |
| Description | Cedric Ghevaert - AstraZeneca |
| Organisation | AstraZeneca |
| Department | AstraZeneca Sweden |
| Country | Sweden |
| Sector | Private |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ryan Hicks at AstraZeneca Sweden involving university stem cells. |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - Rockend, LTD |
| Organisation | University of Cambridge |
| Department | Milner Therapeutics Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Shaun Foy and Rodger Novak of Rockend, Ltd, titled "Production of platelet-like particles in vitro for therapeutics." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University College London - University of Edinburgh |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University College London - University of Edinburgh |
| Organisation | University of Edinburgh |
| Department | MRC Centre for Regenerative Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Wasim Qaseem of University College London and Stuart Forbes of the University of Edinburgh entitled "Immunology Project (UKRMP to UCL) - Universal cells to overcome HLA barriers in regenerative medicine". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University of Bristol |
| Organisation | University of Bristol |
| Department | School of Physiology, Pharmacology and Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Alastair Poole of University of Bristol titled "Biogenesis and Bioengineering of Human Platelets." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Cedric Ghevaert - University of Cambridge Material Science |
| Organisation | University of Cambridge |
| Department | Department of Materials Science & Metallurgy |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Sohini Kar-Narayan of the University of Cambridge Department of Materials Science & Metallurgy. |
| Impact | Outputs expected |
| Start Year | 2020 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | Babraham Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Cedric Ghevaert - University of Sheffield - University of Loughborough - Babraham Research Institute |
| Organisation | University of Sheffield |
| Department | Department of Biomedical Science |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Cedric Ghevaert - Collaborative project |
| Collaborator Contribution | Collaboration with Ivana Barbaric (University of Sheffield), Rob Thomas (Loughborough University), Wolf Reik (Babraham Research Institute) and Roger Barker (Wellcome-MRC Cambridge Stem Cell Institute) entitled "The Pluripotent Stem Cells and Engineered Cell (PSEC) hub". |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2018 |
| Description | Computational analyses of spatial transcriptomic data and collaboration on limb development manuscript. |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Computational analyses of spatial transcriptomic data and collaboration on limb development manuscript. |
| Collaborator Contribution | Computational analyses of spatial transcriptomic data and collaboration on limb development manuscript. |
| Impact | Our group has recently started collaborating with Sarah Teichmann's laboratory at the Sanger Institute to obtain help for computational analyses of our recently acquired spatial Transcriptomics data. This collaboration is multi-disciplinary (bioinformatics and regenerative biology). During this process, I have given intellectual input on a paper that the Teichmann group had been assembling that is now in the process of being submitted. |
| Start Year | 2021 |
| Description | Elisa Laurenti - Max Planck Institute of Immunobiology and Epigenetics |
| Organisation | Max Planck Society |
| Department | Max Planck Institute of Immunobiology and Epigenetics |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CSCI PI Elisa Laurenti - Collaborative project |
| Collaborator Contribution | Collaboration with Nina Cabezas-Wallscheid entitled "Molecular regulation of human haematopoietic stem cell quiescence." |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | George Vassiliou - Cambridge MRC Cancer Unit |
| Organisation | University of Cambridge |
| Department | MRC Cancer Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI George Vassiliou - Collaborative project |
| Collaborator Contribution | Collaboration with Christian Frezza of the University of Cambridge's MRC Cancer Unit entitled "Investigation of metabolic vulnerabilities of clonal haematopoiesis clones." |
| Impact | Outputs and outcomes expected 2021 |
| Start Year | 2019 |
| Description | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York |
| Organisation | University of Tokyo |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York |
| Collaborator Contribution | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York |
| Impact | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Bertie Gottgens, also involving University of York |
| Start Year | 2021 |
| Description | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University |
| Organisation | University of Kumamoto |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University |
| Collaborator Contribution | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University |
| Impact | Joint MRC-Japan Agency for Medical Research and Development (AMED) with Elisa Laurenti and Simon Mendez Ferrer, also involving Keio University |
| Start Year | 2021 |
| Description | Joo-Hyeon Lee - University of Cambridge, Department of Biochemistry |
| Organisation | University of Cambridge |
| Department | Department of Biochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Joo-Hyeon Lee - Collaborative project |
| Collaborator Contribution | Collaboration with Kathryn Lilley of University of Cambridge's Department of Biochemistry. |
| Impact | Outcomes expected 2021 |
| Start Year | 2020 |
| Description | Joo-Hyeon Lee - University of Cambridge, Department of Surgery |
| Organisation | University of Cambridge |
| Department | Department of Surgery |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Joo-Hyeon Lee - Collaborative project |
| Collaborator Contribution | Lee lab collaborates with Dr Kourosh Saeb-Parsy's group for receiving human lung tissue samples to develop patient-derived human lung organoid models. |
| Impact | Outputs expected 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - Abcam |
| Organisation | Abcam |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Anne Wiblin of Abcam related to anitbodies validations. |
| Impact | Outputs and outcomes expected to begin in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - Bit.bio |
| Organisation | Bit.Bio |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Mark Kotter of Bit.bio related to research in forward programming. |
| Impact | Outputs and outcomes expected to begin in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - California Institute of Technology |
| Organisation | California Institute of Technology |
| Department | Division of Biology and Biological Engineering (BBE) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Magdalena Zernicka-Goetz of Caltech's Division of Biology and Biological Engineering. |
| Impact | Outputs and outcomes expected beginning in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - University of California at Davis |
| Organisation | University of California, Davis |
| Department | UC Davis College of Biological Sciences |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Gerald Quon of UC-Davis College of Biological Sciences |
| Impact | Outputs and outcomes expected beginning 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - University of Oxford |
| Organisation | University of Oxford |
| Department | Department of Physiology, Anatomy and Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Shankar Srinivas of Oxford's Department of Physiology, Anatomy and Genetics. |
| Impact | Outputs and outcomes beginning in 2021 |
| Start Year | 2020 |
| Description | Ludovic Vallier - University of Washington |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CSCI PI Ludovic Vallier - Collaborative project |
| Collaborator Contribution | Collaboration with Kelly Stevens of the University of Washington's College of Engineering |
| Impact | Outputs and outcomes beginning in 2021 |
| Start Year | 2020 |
| Description | Roger Barker - Lund University |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CSCI PI Roger Barker - Collaborative Project |
| Collaborator Contribution | Collaboration with Johan Jakobsson titled "Role of transposons in driving inflammation in Parkinson's Disease". |
| Impact | Outputs expected |
| Start Year | 2020 |
| Description | Roger Barker - Novo Nordisk - Cambridge Design Partnership |
| Organisation | Cambridge Design Partnership |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CSCI PI Roger Barker - Collaborative project |
| Collaborator Contribution | Collaboration between Roger Barker, Novo Nordisk and the Cambridge Design Partnership to develop dopaminergic stem cells for the treatment of Parkinson's Disease. |
| Impact | Outputs and outcomes beginning in 2021. |
| Start Year | 2020 |
| Description | Roger Barker - Novo Nordisk - Cambridge Design Partnership |
| Organisation | Novo Nordisk |
| Country | Denmark |
| Sector | Private |
| PI Contribution | CSCI PI Roger Barker - Collaborative project |
| Collaborator Contribution | Collaboration between Roger Barker, Novo Nordisk and the Cambridge Design Partnership to develop dopaminergic stem cells for the treatment of Parkinson's Disease. |
| Impact | Outputs and outcomes beginning in 2021. |
| Start Year | 2020 |
| Description | Sanjay Sinha - AstraZeneca |
| Organisation | AstraZeneca |
| Department | AstraZeneca Sweden |
| Country | Sweden |
| Sector | Private |
| PI Contribution | CSCI PI Sanjay Sinha - Collaborative project |
| Collaborator Contribution | Collaborative research with Ryan Hicks of AstraZeneca Sweden. |
| Impact | Outputs and outcomes beginning in 2021 |
| Start Year | 2020 |
| Description | Sanjay Sinha - Imperial College London |
| Organisation | Imperial College London |
| Department | Department of Bioengineering |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CSCI PI Sanjay Sinha - Joint Grant awarded by Kusuma Trust |
| Collaborator Contribution | The Kusuma Trust awarded a grant to Dr Sanjay Sinha (Wellcome - MRC Cambridge Stem Cell Institute) and Prof Molly Stevens (Imperial College London) to work together on developing an innovative material strategy to heal the heart. This follows on from some initial successful research carried out by the Stevens Group to develop cardiac patches. This next phase of research will use the expertise of both groups in cardiac cell biology and biomaterials to develop pioneering new materials. If successful, this therapeutic approach will strengthen and support heart regeneration and is potentially a highly promising solution for the treatment of heart failure. We look forward to seeing the outcome of this research and the impact that it could have. |
| Impact | Outcomes expected beginning 2021 |
| Start Year | 2020 |
| Title | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies - Brian Huntly |
| Description | This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2 dose (RP2D) based on the safety, PK, and PD profiles observed after oral administration of GSK525762. Eligible subjects with select relapsed refractory hematological malignancies (acute myeloid leukemia [AML], non-Hodgkin's Lymphoma [NHL]and multiple myeloma [MM]), will be enrolled in the QD and/or BID dosing cohorts until a MTD is established. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent. . Upon determination of the MTD, twice daily (BID) dosing cohorts may be opened to collect additional safety data and evaluate the preliminary efficacy of GSK525762 administered BID. Part 2 will explore clinical activity at the MTD or RP2D; separate expansion cohorts will be planned for acute myeloid leukemia (AML), non-Hodgkin's Lymphoma (NHL, including an exploratory sub-cohort of subjects with myc and B-Cell Leukemia (BCL)2 and/or BCL6 rearrangements/overexpression [double- and triple-hit lymphoma]), and multiple myeloma (MM). This is the first study of this agent to be conducted in subjects with these relapsed and/or refractory hematological malignancies for which no standard therapies are anticipated to result in a durable remission. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2021 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | The results of this study are still being evaluated, but this is the first study of this agent to be conducted in subjects with these relapsed and/or refractory hematological malignancies for which no standard therapies are anticipated to result in a durable remission. Update at close of trial - Results of the trial were published in Dawson et al, Clin Cancer Res, 2022. Anti-tumour activity from GSK525762 molibresib was observed with. However found its use was associated with gastrointestinal and thrombocytopenia toxicities which resulted in its use being limited. Further investigation of molibresib as part of combination therapies is under consideration. |
| URL | https://clinicaltrials.gov/show/NCT01943851 |
| Title | A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) - Roger Barker |
| Description | This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB). Update at close of study - THIS STUDY SHOWED NO MAJOR BENEFITS BUT WAS THE FIRST EVER STUDY IN HUNTINGTON'S DISEASE TO LOOK AT HIPPOCAMPAL FUNCTION IN THIS CONDITION, WHICH HAS NOW ALLOWED US TO PURSUE OTHER STUDIES EXPLORING THIS FURTHER. IT ALSO SHOWED US HOW TO UNDERTAK SUCH SAMLL TARGETED TRIALS IN HD WHICH WE HAVE TAKEN ON WITH A NEW STUDY CALLED FELL-HD, LOOKING AT FELODIPINE IN EARLY STAGE DISEASE. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | The results of this clinical trial are still being assessed. |
| Title | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease - Roger Barker |
| Description | This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in patients with manifest Huntington's disease (HD). Update at close of trial - THE COMPANY ARE NOW STARTING A NEW TRIAL WITH THIS AGENT AND WE ARE A SITE FOR THIS. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Update at close of trial - THE COMPANY ARE NOW STARTING A NEW TRIAL WITH THIS AGENT AND WE ARE A SITE FOR THIS. |
| Title | A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial |
| Description | A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial. Update from |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2019 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | The primary objective is to establish the safety and tolerability of bexarotene in the treatment of relapsing remitting multiple sclerosis. Update from paper PMID: 34418398 DOI: 10.1016/S1474-4422(21)00179-4 Background: Progressive disability in multiple sclerosis occurs because CNS axons degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma agonists promote remyelination. We aimed to assess the safety and efficacy of a non-selective retinoid X receptor agonist in promoting remyelination in people with multiple sclerosis. Methods: This randomised, double-blind, placebo-controlled, parallel-group, phase 2a trial (CCMR One) recruited patients with relapsing-remitting multiple sclerosis from two centres in the UK. Eligible participants were aged 18-50 years and had been receiving dimethyl fumarate for at least 6 months. Via a web-based system run by an independent statistician, participants were randomly assigned (1:1), by probability-weighted minimisation using four binary factors, to receive 300 mg/m2 of body surface area per day of oral bexarotene or oral placebo for 6 months. Participants, investigators, and outcome assessors were masked to treatment allocation. MRI scans were done at baseline and at 6 months. The primary safety outcome was the number of adverse events and withdrawals attributable to bexarotene. The primary efficacy outcome was the patient-level change in mean lesional magnetisation transfer ratio between baseline and month 6 for lesions that had a baseline magnetisation transfer ratio less than the within-patient median. We analysed the primary safety outcome in the safety population, which comprised participants who received at least one dose of their allocated treatment. We analysed the primary efficacy outcome in the intention-to-treat population, which comprised all patients who completed the study. This study is registered in the ISRCTN Registry, 14265371, and has been completed. Findings: Between Jan 17, 2017, and May 17, 2019, 52 participants were randomly assigned to receive either bexarotene (n=26) or placebo (n=26). Participants who received bexarotene had a higher mean number of adverse events (6·12 [SD 3·09]; 159 events in total) than did participants who received placebo (1·63 [SD 1·50]; 39 events in total). All bexarotene-treated participants had at least one adverse event, which included central hypothyroidism (n=26 vs none on placebo), hypertriglyceridaemia (n=24 vs none on placebo), rash (n=13 vs one on placebo), and neutropenia (n=10 vs none on placebo). Five (19%) participants on bexarotene and two (8%) on placebo discontinued the study drug due to adverse events. One episode of cholecystitis in a placebo-treated participant was the only serious adverse event. The change in mean lesional magnetisation transfer ratio was not different between the bexarotene group (0·25 percentage units [pu; SD 0·98]) and the placebo group (0·09 pu [0·84]; adjusted bexarotene-placebo difference 0·16 pu, 95% CI -0·39 to 0·71; p=0·55). Interpretation: We do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome. However, statistically significant effects were seen in some exploratory MRI and electrophysiological analyses, suggesting that other retinoid X receptor agonists might have small biological effects that could be investigated in further studies. |
| Title | ADIPOA-2 Clinical Trial - Andrew McCaskie |
| Description | Osteoarthritis (OA) is an incurable and debilitating disease. It has been identified as the world's eleventh highest contributor to disability and affects over 70 million Europeans. There is currently no treatment to prevent progression of the disease. In the absence of effective pharmacological, biological or surgical treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential treatments for this condition. Autologous adipose-derived mesenchymal stromal cells (ASCs) are an attractive option for these cellular therapies because of the abundance of tissue, high frequency of MSCs, and minimally invasive harvest procedure. The EU consortium ADIPOA has shown in a 'first in man' 2-centre Phase I safety study that intraarticular injection of a single dose of autologous ASCs to the knee (18 patients, 12 month follow-up) was well-tolerated, had no adverse effects, and resulted in an improvement in pain score and functional outcome. ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. ADIPOA-2 will carry out a multi-centre, randomized clinical trial comparing the use of culture-expanded, autologous adult ASCs in subjects with knee OA with injected Hyaluronan (another widely used therapeutic approach for knee degeneration). This study will involve two major elements: the production of consistent batches of high-quality autologous ASCs under GMP-compliant conditions and the delivery of these cell doses to patients in a trial which will meet all national and European regulatory and ethical standards and which will provide a definitive demonstration of the safety and efficacy of ASCs as a therapy for osteoarthritis. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | ADIPOA-2 will build on the work of ADIPOA to deliver a large-scale clinical trial in regenerative medicine for OA. The purpose of the project is to design and implement a phase IIb study to assess the safety and efficacy of autologous (patient-derived) ACSs in the treatment of advanced OA of the knee. The cells will be prepared from samples of adipose tissue harvested from patients by lipoaspiration. |
| URL | https://adipoa2.eu/ |
| Title | An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue in Patients with Parkinson's disease |
| Description | The Transeuro Transplant study is a trial which will involve grafting foetal tissue into the brain of patients with Parkinson's disease, who are already been followed in the observational study. The tissue inserted in the brain is to help replace and rebuild lost dopamine from the brain due to Parkinson's disease. Only 20 patients will be selected for the transplant. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Clinical trials of cell therapy in PD patients were first performed in Lund in the late 1980s, followed by a number of similar, small trials in other European and North American centres. These initial studies performed on small groups of advanced PD patients were all open label but firmly established safety of the procedure. The results obtained in these trials have shown that the grafted dopaminergic [DA] neurons can survive and function long-term, over more than 10 years, and that some patients have shown clear clinical benefits, especially with respect to their bradykinesia and rigidity, with reductions in L-dopa requirements. Using functional imaging it has also been shown that the grafted DA neurons can restore striatal DA release and provide a sustained re-activation of motor cortical areas, i.e. key areas that were underactive prior to grafting. Post-mortem studies have shown excellent long-term survival of the grafted DA neurons, notwithstanding the observation that some of the long-term surviving transplants (at 12-15 years after grafting) have now been shown to contain signs of PD-related pathologies, i.e. neuronal Lewy-bodies and alpha-synuclein positive inclusions in the grafts. However, such changes have been observed only in some and not in all patients and when seen the extent of the pathology is limited to a small number of the grafted DA cells and the clinical consequence, if any, not known. However, the outcomes of two NIH sponsored double blind placebo controlled trials, which published their main findings in 2001 and 2003, have raised major concerns. In both these trials the grafted patients did not show any significant improvement overall compared to sham-operated controls at 1 and 2 years post grafting. Furthermore, a significant number of patients in both trials developed GIDs, which in some cases were so severe that further neurosurgery was needed to remedy the situation. The reasons for the variable, and overall poor, outcome in these trials, including the generation of GIDs, have been the subject of much debate but have recently centred on three key elements, with an additional possible fourth element: The selection of patients in terms of clinical phenotype, disease stage and pattern of striatal dopaminergic denervation at the time of grafting; The differences in immunosuppressive regimes and the risk that incomplete immunosuppression in combination with the use of solid graft methods may lead to the development of detrimental immune/inflammatory reactions at the graft site with compromise of the grafted dopamine cell function; The mode of engraftment and differences in graft cell survival, and the risk for inhomogeneous delivery of dopaminergic neurons and the generation of potentially dyskinesia-inducing "patchy" innervations in the host striatum; A final possible element is the composition of the grafted tissue and the ratio of serotoninergic to dopaminergic neurons within the graft. There is emerging evidence that serotoninergic neurons can release dopamine in a relatively unregulated fashion given they lack transporters for it, and as such may use L-dopa as a false transmitter which may not only underlie the development of L-dopa induced dyskinesia's but may also contribute to GIDs. Failure of the NIH trials to demonstrate any overall clinical benefits in the grafted patients, and the unexpected and worrisome development of GIDs in a significant number of patients in these trials has represented a major hurdle for the future development of cell based therapies for PD and it is in this and related areas that this project seeks to move the field forward and go beyond the current state of the art for this treatment approach. This project has gathered together all the available expertise in this area to resolve or reduce the risk of the previous complications seen with VM transplants in patients with PD. We will conduct a new round of clinical trials, involving a step-by-step optimisation of all technical aspects of the grafting procedure and patient selection and assessment, in order to improve clinical efficiency and consistency, in the absence of troublesome dyskinesia's. |
| Title | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies - Roger Barker |
| Description | Entry into the study should occur at the time the participant completes participation in one of the preceding studies. Upon completion of the inclusion visit, eligible participants will receive either RO7234292 (RG6042) every 8 weeks (Q8W) or RO7234292 (RG6042) every 16 weeks (Q16W) by bolus intrathecal injection. Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W. Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Clinical trial has not yet been completed. |
| Title | CABL001A2302: A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors |
| Description | The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs). Patients for this study will be identified based on warning criteria and resistance definition following European Leukemia Network (ELN) 2020 recommendations. In addition, the study will investigate the use of two different posologies. For this, patients will receive asciminib 40 mg (twice-daily) BID or of 80 mg (once daily) once daily (QD). |
| Type | Therapeutic Intervention - Drug |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The trial has only just started and recruitment has not begun at all sites but it offers the prospect of improved treatment for a disease in chronic myeloid leukaemia that can have a significant impact on quality of life and one which, as it disproportionately affects older people, will become increasing prevalent with the ageing of the population. |
| Title | CABL001A2302: A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors. Brian Huntly. |
| Description | This study is an international, multi-center, non-comparative, phase IIIb, treatment optimization study of daily 80 mg asciminib (as either as 40 mg BID of asciminib or as 80 mg QD) in adult patients previously treated with 2 or more TKIs. Up to 30 patients who are intolerant to ongoing TKI treatment but in major molecular response (MMR) will also be allowed to enter the trial. Enrollment will be used to have a balance in the allocation of treatment into either asciminib 40 mg b.i.d. or 80 mg q.d. Although this trial will not be powered to compare both treatments, descriptive data from both treatment groups is expected to provide additional insight into the optimal patient management In patients not achieving MMR at 48 weeks or losing the response after the week 48 up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation. In addition, there must not be any grade 3 or 4 toxicity while on therapy, or persistent grade 2 toxicity, possibly related to asciminib and unresponsive to optimal management. The planned duration of treatment is up to 144 weeks unless patient discontinue from treatment due to unacceptable toxicity, disease progression and/or if treatment is discontinued at the discretion of the investigator or the participant prior to week 144. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Impact | This study is an international, multi-center, non-comparative, phase IIIb, treatment optimization study of daily 80 mg asciminib (as either as 40 mg BID of asciminib or as 80 mg QD) in adult patients previously treated with 2 or more TKIs. Up to 30 patients who are intolerant to ongoing TKI treatment but in major molecular response (MMR) will also be allowed to enter the trial. Enrollment will be used to have a balance in the allocation of treatment into either asciminib 40 mg b.i.d. or 80 mg q.d. Although this trial will not be powered to compare both treatments, descriptive data from both treatment groups is expected to provide additional insight into the optimal patient management In patients not achieving MMR at 48 weeks or losing the response after the week 48 up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation. In addition, there must not be any grade 3 or 4 toxicity while on therapy, or persistent grade 2 toxicity, possibly related to asciminib and unresponsive to optimal management. The planned duration of treatment is up to 144 weeks unless patient discontinue from treatment due to unacceptable toxicity, disease progression and/or if treatment is discontinued at the discretion of the investigator or the participant prior to week 144. |
| Title | DLBCL Interim Response Evaluation for Customised Therapy (DIRECT) - Dan Hodson |
| Description | The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy. Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor. Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable. Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | It is too early to describe the impacts of this clinical trial, but the trial seeks to improve diagnostic measures related to high-grade B cell lymphoma. |
| URL | https://clinicaltrials.gov/ct2/show/NCT04226937?term=NCT04226937&draw=2&rank=1 |
| Title | FELL-HD: A trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease |
| Description | Felodipine is a commonly used antihypertensive drug which is typically administered long-term and is well-tolerated with modest side effects. A clinical trial to investigate the use of felodipine in Huntington's disease is ongoing and is funded by the UK Dementia Research Institute and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC) - Dementia and Neurodegeneration Theme. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | ISRCTN56240656 |
| Impact | Huntington's disease (HD) is a progressive, genetic, neurodegenerative disorder that affects approximately 5,700 people in the UK, with 5 times as many at risk of having inherited the gene. There are currently only limited symptomatic therapies for HD, and these largely target only the motor features. Consequentially, the impact on quality of life and the financial burden of HD is high, with a mean societal cost of £21,605 per person per year, growing to approximately £100,000 when residential care is needed. There is therefore an urgent need for disease-modifying agents for patients with HD. This clinical trial is looking to assess the use of felodipine as a treatment for HD. |
| URL | https://www.isrctn.com/ISRCTN56240656?q=56240656&filters=&sort=&offset=1&totalResults=1&page=1&pageS... |
| Title | Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease - Roger Barker |
| Description | The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study. Update at close of trial - THIS STUDY LED THE WAY FOR A SECOND DOPAMINE GENE THERAPY THAT WE WERE INVOLVED WITH CALLED SUNRISE-PD |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2022 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Update post close of study - THIS STUDY LED THE WAY FOR A SECOND DOPAMINE GENE THERAPY THAT WE WERE INVOLVED WITH CALLED SUNRISE-PD. Please see submission for - Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD) |
| Title | Oral Administration STC-15 in Subjects With Advanced Malignancies |
| Description | This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm. The study is designed to systematically assess safety and tolerability, pharmacokinetics, pharmacodynamics and clinical activity of STC-15 in adult subjects with advanced malignancies. Dose levels for further evaluation in expansion cohorts will be selected based on all available PK, pharmacodynamic, target engagement, efficacy, safety, and tolerability data including long-term safety data beyond dose limiting toxicities (DLTs). The study may be amended to evaluate STC-15 in combination with a Food and Drug Administration-approved standard of care treatment regimen, which could encompass targeted/chemotherapy, radiation therapy and/or immunotherapy with immune checkpoint blockers. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | NCT05584111 |
| Impact | This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm. The study is designed to systematically assess safety and tolerability, pharmacokinetics, pharmacodynamics and clinical activity of STC-15 in adult subjects with advanced malignancies. Dose levels for further evaluation in expansion cohorts will be selected based on all available PK, pharmacodynamic, target engagement, efficacy, safety, and tolerability data including long-term safety data beyond dose limiting toxicities (DLTs). The study may be amended to evaluate STC-15 in combination with a Food and Drug Administration-approved standard of care treatment regimen, which could encompass targeted/chemotherapy, radiation therapy and/or immunotherapy with immune checkpoint blockers |
| Title | RESTORE: Recovery and Survival of Stem Cell Originated Red Cells - Cedric Ghevaert/NHS Blood and Transplant |
| Description | A single centre randomised, controlled phase I cross-over trial in healthy volunteers to assess the recovery and survival of a mini-dose of red blood cells derived from CD34+cells isolated from adult blood vs standard donated red blood cells. Randomised, single blind, cross-over design to compare the recovery and survival of red blood cells manufactured from CD34+ cells isolated from adult blood compared with standard donated red blood cells. The order in which each recipient receives the standard or manufactured red blood cells is randomised and recipients will be blinded to that order. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | There are a small number of patients with rare blood group types for whom NHS Blood and Transplant cannot meet the transfusion requirements. New red blood cells can be grown from human blood stem cells in the laboratory. We hope that this will provide us with a novel transfusion product for these patients in the future, some of whom require regular transfusions throughout life (e.g. for thalassemia or sickle cell disease). |
| URL | https://www.nhsbt.nhs.uk/clinical-trials-unit/current-trials-and-studies/restore/ |
| Title | Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD) - Roger Barker |
| Description | This study consists of two parts. Part A is an open-label dose-escalation phase in which participants are enrolled in cohorts and will receive one of approximately three escalating doses of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which participants will be randomized to either an active group receiving the selected dose from Part A, or to a control group receiving an imitation surgical procedure (ISP). Update at close of study - WE CAN SEE SOME BENEFITS WITH THIS THERAPY SO ITS SHOWS PROOF OF PRINCIPLE AROUND THIS TYPE OF THERAPUTIC INTERVENTION USING DOPAMINE GENE THERAPIES IN ADVANCED PARKINSON'S DISEASE, EVEN THOUGH THE COMPANY STOPPED THE TRIAL FOR FINANCIAL REASONS. |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | This clinical trial is ongoing, and its potential impacts have not yet been assessed. |
| URL | https://clinicaltrials.gov/show/NCT03720418 |
| Title | TAMARIN: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms - Simon Mendez-Ferrer |
| Description | Myeloproliferative neoplasms (MPNs) are blood cancers which affect the normal production of blood cells from the bone marrow. They are caused by changes (mutations) in blood stem cells, frequently in the genes that produce proteins called JAK2, CALR or MPL. MPNs have a risk of developing to an acute leukaemia (a more advanced stage of disease) and currently has no effective cure, apart from bone marrow transplantation which is not possible for many patients. Recent work in mouse studies has suggested that tamoxifen, a drug widely used to treatment breast cancer, may reduce the number of mutated cells by mimicking oestrogen (a female sex hormone) which has a role in the survival and production of new stem cells that give rise to blood cancers. In these studies, tamoxifen prevented the excessive production of blood cells by restoring normal levels of cell death in the mutated cells. This is a single arm, multicentre phase II trial designed to assess if adding tamoxifen to patients receiving therapy for their MPN reduces the number of mutated cells found in the blood by = 50% after 24 weeks of treatment compared to the start of the study. Collection of blood and bone marrow samples will also allow laboratory researchers to study the biological effects of tamoxifen and how this correlates with the patient's disease and response to therapy. Patients will receive treatment with 20mg once daily (oral tablet) of tamoxifen with their normal therapy for their MPN. 42 patients will be recruited from 13-15 UK centres over 12 months. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | The results of this clinical trial are still being evaluated and should be published in the near future. |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005497-38 |
| Company Name | STROMA BIOSCIENCES LIMITED |
| Description | A company whose goal is discovering novel stroma-intrinsic targets and therapeutics specifically targeting these mechanisms in a broad range of diseases. |
| Year Established | 2020 |
| Impact | A company whose goal is discovering novel stroma-intrinsic targets and therapeutics specifically targeting these mechanisms in a broad range of diseases. |
| Company Name | HEPATOTARGET THERAPEUTICS LTD. |
| Description | A company working in biotechnology through the Babraham Research Campus at the University of Cambridge. |
| Year Established | 2019 |
| Impact | A company working in biotechnology through the Babraham Research Campus at the University of Cambridge. |
| Company Name | ABS Biotechnologies GmbH |
| Description | ABS Biotechnologies was founded with the mission to provide patients with safer medicines using our stem cell and cardiovascular expertise. Using IP from a world-leading academic laboratory at the University of Cambridge we strive to eradicate drug-induced heart attacks, strokes, high blood pressure, and irregular heart rhythms. Our goals are to: 1. Promote patient safety through safer drugs We use next-generation stem cell technology for rigorous screening of new drug compounds. This prevents exposing patients to harmful side effects 2. Reduce the costs of drug development Our technology allows for early detection of drug side effects when compounds are still in development so minimising the consequences of side effects emerging during clinical trials or even post-approval. In addition, more accurate testing reduces the risk of erroneously discarding promising candidates during the drug development process. |
| Year Established | 2022 |
| Impact | Has now received 170,000 euros pre-seed funding from the Austrian government |
| Website | https://www.absbiotechnologies.com/index.php |
| Company Name | REGENERATIVE CELL THERAPY CONSULTING LIMITED |
| Description | Consultancy company advising on stem cell therapies |
| Year Established | 2022 |
| Impact | . |
| Company Name | CELLADVICE LTD |
| Description | Consultancy for companies involved in transfusion products or cell therapies. |
| Year Established | 2019 |
| Impact | This consultancy advises companies and practitioners in relation to transfusion products and cell therapies. |
| Company Name | ALVEO THERAPEUTICS LTD |
| Description | In process of raising funds. will be focused on cancer early detection assays |
| Year Established | 2021 |
| Impact | In process of raising funds. will be focused on cancer early detection assays |
| Company Name | ACULIVE THERAPEUTICS LIMITED |
| Description | Newly form company |
| Year Established | 2021 |
| Impact | Newly form company |
| Company Name | XAP THERAPEUTICS LIMITED |
| Description | Start up to produce platelet-like particles in vitro |
| Year Established | 2017 |
| Impact | Start up to produce platelet-like particles in vitro |
| Company Name | TROPOFOUR THERAPEUTICS LIMITED |
| Description | This company is developing compounds to control platelet formation. |
| Year Established | 2019 |
| Impact | The company possesses potentials to impact clinical therapies and research paradigms. |
| Description | Article about STEM PD trial in Observer |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Many people contacted me about the trial |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.theguardian.com/society/2022/dec/04/radical-new-therapy-for-parkinsons-will-use-stem-cel... |
| Description | Article in University of Cambridge |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | This article increased the awareness of the interdisciplinarity of stem cell research, as it was a collaborative project with the Department of Pharmacology |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.cam.ac.uk/stories/weird-naked-mole-rats |
| Description | Article in the Guardian |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Research may reveal why people can suddenly become frail in their 70s | Ageing | The Guardian |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.theguardian.com/science/2022/jun/01/research-may-reveal-why-people-can-suddenly-become-f... |
| Description | Article published in The Sun about Sinha's Lab work on regenerating heart tissue |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Article published in The Sun about Sinha's Lab work on regenerating heart tissue |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.thesun.co.uk/health/17636231/hearts-self-heal-regenerative-medicine/ |
| Description | BBC - The Curious Cases of Rutherford & Fry |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | This podcast focuses on heart health and interviewed Sanjay Sinha to discuss his work on creating a heart patch. This led to increased awareness of his work and requests for further interviews in other press |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.bbc.co.uk/sounds/play/w3ct30j0 |
| Description | BBC News story related to the Nature Communications publication: Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC News story related to the Nature Communications publication: Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. Nature Communications. https://doi.org/10.17863/CAM.64705 |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.stemcells.cam.ac.uk/news/changes-detected-brca1-breast-cells-cancerous |
| Description | BBC news story related to the Nature Publication the Transcriptional changes in the mammary gland during lactation revealed by single cell sequencing of cells from human milk |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC news story related to the Nature Publication the Transcriptional changes in the mammary gland during lactation revealed by single cell sequencing of cells from human milk |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.stemcells.cam.ac.uk/news/live-cells-discovered-human-breast-milk-could-aid-breast-cancer... |
| Description | Black scientists: Challenges, Champions & Change |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Panel discussion event held at JCBC, open to all with a large contingent of University of Cambridge attendees, discussing challenges, champion and change for black scientists. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.eventbrite.co.uk/e/black-scientists-challenges-champions-change-tickets-379079154957 |
| Description | Blog Post for Nature Portfolio Cancer Community's 'Behind the Paper' Blog Series - Elisa Laurenti |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Nature Portfolios online 'Cancer Community' provides a forum where researchers, professional practitioners and other interested parties may discuss current and past research into a variety of scientific topics. The community's 'Behind the Paper' blog series gives researchers who publish their findings in Nature journals an opportunity to describe and discuss their publication and working processes. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://cancercommunity.nature.com/posts/a-transcriptomic-continuum-of-differentiation-arrest-identi... |
| Description | Bluesci podcast: Lab grown organoids and regenerative medicine - Fotis Sampaziotis |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | Podcast with student-run science journalism group Blusci on current research. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Bury St Edmunds PUK branch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Branch PDUK Open Days |
| Year(s) Of Engagement Activity | 2022 |
| Description | CBC on Virtual Tour: Cambridge Children's - David Rowitch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Online presentation livestreamed online and bookable by the public organised by Cambridge Biomedical Campus to share updates about and host Q&A on the Cambridge Childrens project. |
| Year(s) Of Engagement Activity | 2021 |
| Description | CCMR Symposium with patients |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Cambridge Centre for Myelin Repair annual research symposium with invited attendees from patient/carer networks and local MS Society branch groups. |
| Year(s) Of Engagement Activity | 2022 |
| Description | CUH Active group visit to JCBC |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A group of young people who have previously engaged elsewhere on the Cambridge Biomedical Campus (Cambridge University Hospital's ACTIVE group) visited the institute to meet postgraduate students, learn about stem cells, and see our laboratories. |
| Year(s) Of Engagement Activity | 2022 |
| Description | CUH Active work experience |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Multi-day work experience placement for young member of CUH Active group considering applications to undergraduate biomedical science degrees. Shadowing with research groups met earlier in the year when the CUH Active group visited JCBC. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cambourne Crescent group visit to JCBC |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Families of children connected with Cambourne Crescent, is a local Islamic Charitable Trust, visited the institute in support of a researcher's CSCI PE seed fund project, to see where we work and who we work with to try to answer scientific questions. Their participation in hands-on workshops during this visit informed the co-creation of an illustrated resource with diverse representation of roles. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cambourne school STEM week |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Participation in a school science fair with hands-on activities. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cambridge Biomedical Campus Christmas Market |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Bertie Gottgens (Director of CSCI) initiated the idea to host a Christmas Market for those on campus. As a result, three institutes/organisations worked together to pull off the event, which drew around 600 attendees throughout the course of the day. By engaging with charities our PIs work with, our neighbours on campus, local businesses and vendors, and the nearby villages, we were able to generate more interest in CSCI and traffic to our site on campus. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cambridge Festival HeLa book club - Emily Calderbank |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Attendance at a book club session arranged by the University of Cambridge and Gurdon Institute PE teams, to discuss Rebecca Skloot's "The Immortal Life of Henrietta Lacks" as part of the Cambridge Festival. |
| Year(s) Of Engagement Activity | 2021 |
| URL | http://www.henriettacamfest.co.uk/book-club-resources |
| Description | Cambridge PUK branch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Branch PDUK Open Days |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cambridge University Research page |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Undergraduate students |
| Results and Impact | The results from this research are part of the Human Breast Cell Atlas project funded by the MRC, and will hopefully provide a potential early indicator of future breast cancer development. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.cam.ac.uk/research/news/live-cells-discovered-in-human-breast-milk-could-aid-breast-canc... |
| Description | Code for a Change (PE Seed Fund) |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Online bioinformatics coding challenges created by a PhD students to introduce others to research and python programming, available in English and Spanish. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.codeforachange.com |
| Description | Code for a Change website - Mariana Quiroga-Londono |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Online platform with coding challenges in Python to help build skills and challenge users to complete bioinformatics challenges. |
| Year(s) Of Engagement Activity | 2021,2022 |
| URL | http://www.codeforachange.com |
| Description | Conference Organiser/Chair - Neuromatch 3.0 Conference, Theme B: Neural Excitability, Synapses, and Glia - Thora Karadottir |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Based on the successful mind-matching session at the Cognitive Computational Neuroscience (CCN) conference and previous Neuromatch conference with more than 6k attendees, organisers decided to create an online unconference for all neuroscientists. Organisers built a better online experience for neuroscience conferences by making them more open, inclusive, and democratic. Thora was a co-organiser for one of the conference's research themes. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://neuromatch.io/ |
| Description | Cord blood discussion sessions (PE Seed Fund) - Emily Calderbank |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Focus group sessions with potential, expectant or current mothers to discuss the uses of donated umbilical cord blood in research and inform conversations with research nurses and healthcare professionals about common questions, concerns or misconceptions donors may have. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Creative Encounters |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | University of Cambridge scheme matching researchers interested in creative outputs, including poetry, with practicioners, partners and peers elsewhere in the University and leading to an exhibition for the Cambridge Festival. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cure Parkinson's research update |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Research update talk for members of the network of the Cure Parkinson's charity. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Cystic Fibrosis Trust online focus group - Laetitia Pinte; Marta Vila Gonzalez |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Third sector organisations |
| Results and Impact | Zoom focus group with representatives from patient networks and staff teams at the Cystic Fibrosis Trust staff to discuss current research at CSCI and ways of engaging and involving CF patients in future. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Daily Mail news article |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Many people contacted me about the research |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.dailymail.co.uk/news/article-10359873/Britons-suffering-heart-failure-cured-thumb-sized-... |
| Description | Digital Student Outreach during Coronavirus School Closures - Jamie McGinn |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | The Medical Research Zone was a themed zone that ran in the summer term of 2020 as part of I'm a Scientist, Stay at home. The activity helped students stay connected with STEM during the coronavirus closures. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://medical20.imascientist.org.uk/profile/jamiemcginn/ |
| Description | Digital Student Outreach during Coronavirus School Closures - Robyn Macrae |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | The Medical Research Zone was a themed zone that ran in the summer term of 2020 as part of I'm a Scientist, Stay at home. The activity helped students stay connected with STEM during the coronavirus closures. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://medical20.imascientist.org.uk/profile/robynmacrae/ |
| Description | Digital Student Outreach during Coronavirus School Closures - Shaline Fazal |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | The Medical Research Zone was a themed zone that ran in the summer term of 2020 as part of I'm a Scientist, Stay at home. The activity helped students stay connected with STEM during the coronavirus closures. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://medical20.imascientist.org.uk/profile/shalinefazal/ |
| Description | Edinburgh Parkinson's lecture - Roger Barker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Online invited lecture through Zoom to provide a research update for members of the Parkinson's UK community. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Guardian & Health Awareness |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The Blood Health Week article was featured in the Guardian to discuss research breakthroughs that are driving leukaemia treatment and care. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.healthawareness.co.uk/haematology/research-breakthroughs-are-driving-innovations-in-leuk... |
| Description | HDBI Insights Group presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Attendance at, presentation to, and discussion with, the Wellcome-funded HDBI Insights Group, a stakeholder engagement panel focussing on human foetal and embryological tissue donation for research. |
| Year(s) Of Engagement Activity | 2022 |
| Description | HDBI Made The Same Way podcast |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Researchers co-created podcast episodes for a series produced by the Wellcome-funded Human Developmental Biology Initiative, Reform Radio, and the Gurdon Institute at the University of Cambridge. Scientists were matched with MCs to discuss their work and produce orginal musical pieces. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://anchor.fm/made-the-same-way |
| Description | Huntingdon's Disease open day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Huntingdon's Disease open day en day |
| Year(s) Of Engagement Activity | 2022 |
| Description | |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Launch of new Instagram account for the Institute at @SCICambridge, primarily as a channel to r(a) each community or special interest groups and (b) younger students and early career researchers . |
| Year(s) Of Engagement Activity | 2021,2022 |
| URL | http://www.instagram.com/scicambridge |
| Description | Interview for 'Pager' Podcast (s2e2) - Sanjay Sinha |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Every few weeks, listeners tune in to the 'Pager' podcast to hear about the topics changing the future of biology and medicine. The heart is notoriously bad at regenerating following damage to the myocardium. On the horizon are cell therapies that could restore cardiac function following damage. In this episode, Dr Sanjay Sinha, a British Heart Foundation Senior Research Fellow, and a consultant cardiologist at Addenbrooke's hospital, joins us discuss a stem cell derived cardiac 'patch', which could be transplanted into patients for heart repair after myocardial infarction. The potential of cardiac cells derived from iPSCs for personalised approached to treatment, and for modeling disease, are also discussed. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.buzzsprout.com/688397/4794047-regenerating-the-damaged-heart-with-sanjay-sinha |
| Description | Interview for 'Pager' Podcast (s2e5) - Roger Barker |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Every few weeks, listeners tune in to the 'Pager' podcast to hear about the topics changing the future of biology and medicine. In this episode, Dr Roger Barker joins us to discuss our current understanding of Parkinson's disease. The first half of the conversation focuses on the disease process. Is Parkinson's a single disease or a group of connected diseases? How might this difference affect our thinking surrounding Parkinson's? The discussion then switches to the development of cell and gene therapies for Parkinson's. The unique challenges of a cell therapy for the brain, as well as the efficacy of a neurotrophic factor 'GDNF', are both discussed. Dr Barker is the professor of clinical neuroscience at the University of Cambridge, and a consultant neurologist at Addenbrooke's hospital in Cambridge. His lab at the John van Geest Centre for Brain Repair is focused on better understanding both Parkinson's and Huntington's disease, as well as on developing therapies to treat these diseases. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.buzzsprout.com/688397/5141326-parkinson-s-disease-in-2020-with-roger-barker |
| Description | Interview for 'StemCells@Lunch Digested' Podcast (e101) - Jose Silva |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | StemCells@Lunch Digested is a podcast that keeps the public up to date with current research taking place in the stem cell research community. Listeners can hear guest speakers discuss their work, how they got to where they are today and their hopes for the future of stem cell research. The podcast is hosted by King's College London Centre for Stem Cells & Regenerative Medicine. PhD student Christopher Lambert interviews Dr José Silva, a group leader at the Welcome-MRC Cambridge Stem Cell Institute. Dr Silva tells us about his career path from PhD to group leader and his current research in cellular reprogramming. They discuss the importance of collaboration in basic research and the need for a long-term, step-wise approach to progress the field of cellular reprogramming. Dr Silva also looks to the future, talking about his move into creating synthetic embryos. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://soundcloud.com/user-563815853/episode-101-dr-jose-silva-it-is-the-basic-research-that-leads-... |
| Description | Interview for 'StemCells@Lunch Digested' Podcast (e107) - Ludovic Vallier |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | StemCells@Lunch Digested is a podcast that keeps the public up to date with current research taking place in the stem cell research community. Listeners can hear guest speakers discuss their work, how they got to where they are today and their hopes for the future of stem cell research. The podcast is hosted by King's College London Centre for Stem Cells & Regenerative Medicine. Professor Ludovic Vallier, Professor of Regenerative Medicine within the Department of Surgery at Cambridge University and director of the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre hIPSCs (human induced pluripotent stem cells) core facility, is interviewed by PhD student Alice Vickers. He talks about his work using human pluripotent cells to generate pancreas, lung, gut and liver cells. He speaks about how his involvement in industry aims to generate cell types for clinical studies and for cell based therapy. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://soundcloud.com/user-563815853/episode-107-prof-ludovic-vallier-the-drive-is-to-generate-more... |
| Description | Interview for 'StemCells@Lunch Digested' Podcast (e97) - Simon Mendez-Ferrer |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | StemCells@Lunch Digested is a podcast that keeps the public up to date with current research taking place in the stem cell research community. Listeners can hear guest speakers discuss their work, how they got to where they are today and their hopes for the future of stem cell research. The podcast is hosted by King's College London Centre for Stem Cells & Regenerative Medicine. PhD Student Dr Beibei Du speaks with Dr Simón Méndez-Ferrer, a Reader in Transfusion Medicine at the University of Cambridge. They discuss what controls blood stem cell behaviour, including whether you are awake or asleep. Simón also talks about how understanding what makes blood stem cells move can be used in stem cell transplants to treat blood cancers. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://soundcloud.com/user-563815853/episode-97-dr-simon-mendez-ferrer-how-can-targeting-where-stem... |
| Description | Interview for 'The Academinist' Podcast (e4) - Oluwaseun Ogundele |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The podcast about equality and feminism in STEM. Join Rebecca & Jodi - two neuroscientists based in London - as they discuss with guests how inequality affects womxn and minorities in STEM*, and ponder what we can all do to fix this as feminists in science. Also, we are joined by Stem Cell Research Assistant and Science Activist Oluwaseun Ogundele. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://podcasts.apple.com/gb/podcast/being-visible-with-oluwaseun-ogundele/id1513830838?i=100048941... |
| Description | Interview for 'The Stem Cell Podcast' (e177) - Ludovic Vallier |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Stem Cell Podcast was launched in 2013 by two research scientists, Drs Yosif Ganat and Chris Fasano. Their goal was to create an accessible, entertaining resource for scientists to keep current on the latest developments in stem cell research, as well as to interview key influencers in the stem cell field about their work and perspectives on the field. Dr. Ludovic Vallier is a Professor of Regenerative Medicine at the Cambridge Stem Cell Institute and Director of the NIHR Cambridge Biomedical Centre hiPSC core facility. His lab studies the basic mechanisms controlling the differentiation of pluripotent cells into endoderm progenitors from which the pancreas, lung, gut and liver originate. He discussed his research and the current state of stem cell biology within this podcast episode. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://stemcellpodcast.com/ep-177-molecular-mechanisms-of-differentiation-featuring-dr-ludovic-vall... |
| Description | Interview for 'Your Digital Mentor' Podcast (s1e5) - Oluwaseun Ogundele |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | 'Your digital mentor' podcast is a series that aims to provide access to conversations around mentoring and other aspects of research and career development, with a focus on LMICs. Episode Summary: Short description: We discuss what imposter syndrome is and how to get out of your own way. Guests: Daniela Robles and Oluwaseun Ogundele. Prologue: Isabela Malta. Episode description: Imposter syndrome is a psychological phenomenon when a person feels they are a fraud or don't deserve their achievements and that you achieved them solely through luck. This phenomenon disproportionately affects women and people of colour, but anyone can succumb to it. It happens when someone cannot internalise their own success. In this episode we discuss these internal narratives and how to overcome them and 'reach for the stars'! |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://your-digital-mentor.simplecast.com/episodes/imposter-syndrome-pS61bOE5 |
| Description | Interview for European Pharmaceutical Review - Roger Barker |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Dr Roger Barker, University of Cambridge, UK and Eric Anthony, International Society for Stem Cell Research (ISSCR), describe how stem cells are regulated around the world and why this is important for patient safety. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.europeanpharmaceuticalreview.com/article/117011/stem-cells-in-the-clinic-how-are-they-re... |
| Description | Interview for International Society of Hematology's 'Simply Blood' Blog - Elisa Laurenti |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | As members of the International Society of Hematology (ISEH), we place great value in the communication and collaboration occurring between our colleagues around the world. This blog has been established to help continue those interactions beyond the annual meeting and past the purely scientific realm. We hope Simply Blood will act as a lively platform for open discussions about how we function, grow and engage as scientists. This week on Simply Blood we are continuing our 2020 Interview Spotlight Series. In Part II we are featuring the ISEH 2020 New Investigator's Invitee: Elisa Laurenti, MBS; PhD. Dr. Laurenti answers questions about her work, trends in hematology, mentorship, and more. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.simplyblood.org/2020/07/2020-interview-spotlight-series-part-ii.html |
| Description | Interview for October 2020 Branch Meeting (Parkinson's UK, West Hertfordshire) - Roger Barker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Professor Roger Barker, Head of the Brain Repair Centre in Cambridge, was the special guest of the West Hertfordshire branch of charity Parkinson's UK at its October branch meeting. In a fascinating talk, Prof. Barker took attendees through some of the previous research into dopamine and some exciting new dopamine cell therapies for repairing the brain in Parkinson's. The presentation included outlining which patients may best benefit from such an intervention as well as the very latest news on stem cell transplants for Parkinson's patients in the UK and globally. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://parkinsons-westherts.org.uk/october-meeting-with-professor-roger-barker/ |
| Description | Interview for Social Media Broadcast (Allen Institute YouTube) - Thora Karadottir |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Allen Distinguished Investigator Ragnhildur Thóra Káradóttir describes how the tools that are available now are helping to support neuroscience, immunology and psychiatric disease research better than ever before. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=A2IRX46Stus |
| Description | Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Adam Young |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, Dr Adam Young (Franklin Group) describes how he refocused his work using viruses as 'tools' to investigate the interaction between stem cells and immune cells in the brain. Now, his team are exploring similarities between the coronavirus, and the measles, mumps and rubella viruses and their long-standing vaccines. Early results from the team's Covid-19 research are available in a MedRxiv preprint at https://doi.org/10.1101/2020.04.10.20053207v1 |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=gamjz_9VL2A |
| Description | Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Cedric Ghevaert |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film Dr Cédric Ghevaert introduces his group, who are investigating blood clotting in coronavirus patients. Amie, James, Moyra and Winnie answered our questions about the team's recent work with collaborators at the University of Bristol. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=DWSLc8lcRzA |
| Description | Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Fotios Sampaziotis |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, Dr Fotios Sampaziotis (Vallier group), shares how he discovered his work on stem-cell derived bile duct 'organoids' could provide a potential mechanism to study virus uptake and screen drugs to fight the pandemic. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=GUOC2jr9r74 |
| Description | Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Maria Colzani |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, we meet Dr Maria Colzani from the Sinha Group. Maria is working with colleagues on a collaborative project to investigate heart tissue damage seen in coronavirus patients. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=jCYbR3pUrKI |
| Description | Interview for Social Media Broadcast (Cambridge Stem Cell Institute YouTube) - Nicole Mende and Fernando Calero |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A new online series of short personal interviews with Cambridge Stem Cell Institute researchers exploring how they are adapting their research to investigate Covid-19. In this film, we hear from members of the Göttgens and Laurenti Groups who are taking part in a collaborative Cambridge project on coronavirus. Dr Fernando Calero and Dr Nicole Mende describe their work using genomic techniques to study Covid-19 patient samples. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=8-U4Qnb0wk0 |
| Description | Interview for Social Media Broadcast (Lucy Cavendish College, University of Cambridge YouTube) - Aishwarya Jacob |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Since the first UK COVID-19 lockdown began, Lucy Cavendish College at the University of Cambridge has invited members of its College community to provide information about their lives and research in the form of presentations and blog posts. This fascinating talk details Dr Aishwarya Jacob's career in cancer-related research and Cardiovascular Biology, as well as her future dreams to clone dinosaurs. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.lucy.cam.ac.uk/events/wait-why-am-i-here-again-and-how-did-i-get-here-tale-confused-post... |
| Description | Interview for Social Media Broadcast (seuninscience YouTube) - Elena Corujo-Simon |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | In this series, Oluwaseun, a (British Nigerian) Science Research Assistant working in Stem Cell Research at the Wellcome-MRC Cambridge Stem Cell Institute, explores the narrative of black girl in science, the reality of the lack of BME representation in a predominantly white working field and her journey and experience in this STEM field. The channel hopes to represent a platform to inspire others like her to keep the hustle and live the dream in reality. She regularly interviews fellow scientists and has discussions about their career progressions, with some emphasis on issues in Academia such as the gender gap, lack of representation in science, being a minority in STEM and so forth. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=L2kNI5T0uoA |
| Description | Interview for Social Media Broadcast (seuninscience YouTube) - Elisa Laurenti |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | In this series, Oluwaseun, a (British Nigerian) Science Research Assistant working in Stem Cell Research at the Wellcome-MRC Cambridge Stem Cell Institute, explores the narrative of black girl in science, the reality of the lack of BME representation in a predominantly white working field and her journey and experience in this STEM field. The channel hopes to represent a platform to inspire others like her to keep the hustle and live the dream in reality. She regularly interviews fellow scientists and has discussions about their career progressions, with some emphasis on issues in Academia such as the gender gap, lack of representation in science, being a minority in STEM and so forth. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=xM5x3VmDwO4 |
| Description | Interview for Wall Street Journal's 'The Future of Everything' Podcast (Episode: The Blood of the Future...) - Cedric Ghevaert |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Research into making blood in the lab for use in the clinic is an area the Ghevaert group have been building up expertise over the past decade. However, the recent Covid-19 pandemic has brought greater awareness to the possibilities offered by producing blood in the lab. As the Wall Street journal's article and podcast highlight, during the peak of the pandemic the number of blood donations was greatly reduced and this reduction has led to an increased understanding of the need to look for alternatives to donations to maintain blood supplies. The group have developed a particular expertise in the production of platelets and red cells from human pluripotent stem cells. The team are using and developing methodologies that can produce clinical grade products within the constraints of affordable manufacturing processes. Platelets are the smallest cell in the body and are responsible for key functions such as blood clotting and red cells are essential for carrying oxygen around the body. In the interview, Cédric talks about the group's research and the planned clinical trial RESTORE, which is currently in development. The trial will be the first-in-human clinical trial of red blood cells grown in the laboratory from adult donor blood stem cells and aims to recruit its first patient towards the end of Spring 2021. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.stemcells.cam.ac.uk/news/2018the-blood-of-the-future-could-be-made-in-a-lab2019-2013-dr-... |
| Description | Invited Speaker - 13th International Symposium on Health Informatics and Bioinformatics - Ana Cvejic |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The International Symposium on Health Informatics and Bioinformatics (HIBIT) is now in its thirteenth year. The symposium aims to bring together academics, researchers and practitioners who work in these popular and fulfilling areas and to create the much-needed synergy among medical, biological and information technology sectors. HIBIT is one of the few conferences emphasizing such synergy. HIBIT provides a forum for discussion, exploration and development of both theoretical and practical aspects of health informatics and bioinformatics and a chance to follow current research in this area by networking with other bioinformaticians. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://hibit2020.sabanciuniv.edu/speakers/ |
| Description | Invited Speaker - 2020 UK-Japan Neuroscience Symposium - Thora Karadottir |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The third "UK-Japan Neuroscience Symposium" was held in Edinburgh at the John McIntyre Conference Centre on 3-5 February 2020. The meeting was co-sponsored by the Medical Research Council (MRC) and the Japan Agency for Medical Research and Development (AMED). Building on the success of the London 2018 and Chiba 2019 meetings of the two Neuroscience communities, the Edinburgh 2020 meeting aimed to further establish collaborative links and exchange of ideas between the two countries. The Symposium comprised two days of talks (20 minutes plus 5 minutes discussion each) and poster sessions from UK and Japanese Neuroscience scientists. The Symposium covered a wide range of topics including "Advanced imaging methods for understanding brain function", "Strategies and synaptopathy of neurodegenerative conditions", and "Synapse and circuit development in relation to neuropsychiatric conditions". Thora provided a presentation on Day Two entitled "Oligodendrocyte precursor cells become heterogeneous with age: different functional cell states". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.bna.org.uk/mediacentre/events/uk-japan-neuroscience-symposium-2020/ |
| Description | Invited Speaker - 2nd NCRI AML Academy - Brian Huntly |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Sessions will cover the management of older (and younger) adults with AML, emerging drug and antibody targeted therapies, genomics in diagnosis and management, novel therapeutic strategies in relapsed AML, the David Grimwade memorial lecture and a transplant roundtable (presented cases with panel discussion). In the afternoon, the masterclasses will be based on management of relapsed AML and nursing and the day will end with a debate: DA is still the standard induction therapy for all fit AML patients in the UK. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.rcpath.org/event/2nd-ncri-aml-academy.html |
| Description | Invited Speaker - 2nd Stem Cells UK Conference - Elisa Laurenti |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This one day meeting aims to bring together stem cell researchers from across the UK to share research ideas, forge collaborations and meet friends old and new. Elisa presented a research paper entitled "Haematopoietic stem and progenitor cell landscapes: location matters". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.stemcells.cam.ac.uk/files/stem_cells_uk_23.11.20_programme_final.pdf |
| Description | Invited Speaker - 2nd Stem Cells UK Conference - Ludovic Vallier |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This one day meeting aims to bring together stem cell researchers from across the UK to share research ideas, forge collaborations and meet friends old and new. Ludovic presented a research paper entitled "Function of cell cycle in stem cell differentiation". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.stemcells.cam.ac.uk/files/stem_cells_uk_23.11.20_programme_final.pdf |
| Description | Invited Speaker - Cold Spring Harbor Asia Conference, Frontiers in Single Cell Genomics (Oct 2020) - Bertie Gottgens |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The conference included six oral sessions and one poster session covering the latest findings across many topics in Single Cell. Many talks were selected from the openly submitted abstracts on the basis of scientific merit and relevance. Social events throughout the conference provided ample opportunity for informal interactions. Major Topics included: 1.Technology development 2. Developmental Biology 3. Cancer Biology 4. Computational biology 5. Single cell epigenomics 6. Single cell transcriptional profiling 7. Single cell DNA analysis 8. Single cell imaging 9. Next-generation sequencing Bertie served as one of the twenty-four invited speakers. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.csh-asia.org/?content/404 |
| Description | Invited Speaker - Cold Spring Harbor Laboratory, 8th Summer Conference on Glia in Health and Disease Virtual Conference 2020 - Thora Karadottir |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The eighth summer conference on Glia in Health & Disease went fully virtual and began late morning EDT on Thursday, July 16, 2020. It ended late afternoon EDT on Sunday, July 19, 2020. Oral sessions were confined to later morning and afternoon sessions EDT to maximize access by participants from around the world. The proposed meeting assembled the leaders in the field, together with junior faculty, postdoctoral fellows and graduate students, to discuss new, cutting-edge developments in the study of all aspects of glial biology in health and disease. The format of the meeting included a number of virtual oral sessions and a virtual poster session throughout. Each oral session included invited speakers and speakers selected from submitted abstracts. For this reason, abstracts from accomplished junior and senior investigators were warmly invited. Thora served as an invited Co-Chair. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://meetings.cshl.edu/meetings.aspx?meet=GLIA&year=20 |
| Description | Invited Speaker - Developmental Biology 11th course: From Stem Cells to Morphogenesis - Joo-Hyeon Lee |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | The objective is to expose the students to the recent concepts in Developmental Biology, including highlighting their important contribution to the stem cell field and clinical sciences. Various domains of the Developmental Biology field are addressed, not only across the variety of embryonic models but also across the diversity of approaches (large-scale and translational approaches, mathematical modeling, biophysical approaches). |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://training.institut-curie.org/courses/developmental-biology-8 |
| Description | Invited Speaker - Global K-BioX Seminar - Joo-Hyeon Lee |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation entitled "Stem cells and their dynamic niche in lung regeneration". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://kbiox.org/seminar/seminar.php?boardid=kbxseminar&mode=view&idx=4&sk=&sw=&offset=&category=%E... |
| Description | Invited Speaker - International Society for Stem Cell Research Digital Meeting on Organoids - Joo-Hyeon Lee |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The International Society for Stem Cell Research (ISSCR) will host a four-part digital meeting series featuring a global line-up of speakers who will discuss their latest organoid research. Applying Organoids: The 3D Frontier, co-sponsored by STEMCELL Technologies, will be moderated by Melissa Little, PhD, Murdoch Children's Research Institute, Australia and Toshiro Sato, PhD of Keio University School of Medicine. Each installment of the meeting series will be 90 minutes and include presentations around emerging research and a question and answer session with all presenting scientists. Part I on 7 October will explore research using adult and pluripotent stem cell-derived organoids to recapitulate and understand human development processes, the development of individual endodermal derivatives as well as their organization into complex functional units, and modeling complex human neuropsychiatric disease. Joo participated in "Part 2: Modeling Development and Disease II". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.isscr.org/news-publicationsss/isscr-news-articles/article-listing/2020/10/01/isscr-launc... |
| Description | Invited Speaker - London Stem Cell Network/Bio-Techne Organoid Virtual Workshop - Joo-Hyeon Lee |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Bio-Techne is proud to be partnering with the London Stem Cell Network (LSCN) to present our first Stem Cell and Organoid Virtual Workshop. Please join us for this exciting event to learn more from leading experts on the advances in stem cells and organoids to help further your projects. Joo gave a presentation entitled "Inflammatory Niches Direct Lung Regeneration". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://info.bio-techne.com/LSCN-OrganoidVirtualWorkshop_LP-webinar-main.html |
| Description | Invited Speaker - MRC Human Genetics Unit Symposium - Ana Cvejic |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Ana was invited to speak at the 2020 MRC Human Genetics Unit Symposium, where she provided a presentation entitled "Investigating human blood development at the single-cell level." |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.ed.ac.uk/files/atoms/files/aberrant_cell_programme.pdf |
| Description | Invited Speaker - MSVirtual2020, 8th Joint ACTRIMS-ECTRIMS Meeting - Robin Franklin |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Robin spoke during the 'European Charcot Foundation Symposium', where he presented a talk entitled 'Potential Targets for Remyelination'. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://msvirtual2020.org/ |
| Description | Invited Speaker - The 25th Congress of the European Hematology Association, Molecular Haemopoiesis Workshop Symposium - Ana Cvejic |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Ana was invited to speak at a workshop for the 25th Congress of the European Hematology Association. Information about the virtual conference is as follows: The world has changed tremendously, due to the impact of COVID-19 and for the first time in its history, EHA organized the Annual Congress in a full virtual edition: EHA25 Virtual. Not only was the 25th EHA Congress a success, it also reached a ground-breaking record of nearly 27,000 registrations. Participants were able to access latest hematology and sub-specialty news, unpublished clinical and translational research results, and new evidence-based approaches to diagnosis and treatment. A wealth of scientific and educational content was shared, including special thematic sessions focused on topics such as: Acute leukemia, Chronic lymphoid neoplasms, Chronic myeloid neoplasms, Coagulation disorders, Immunology, Lymphoma, and Red and white cell disorders. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://library.ehaweb.org/eha/#!*menu=6*browseby=3*sortby=2*ce_id=1766*featured=16775 |
| Description | Invited Speaker - The 82nd Annual Meeting of the Japanese Society of Hematology - Bertie Gottgens |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The main theme of this congress was "Exploring diversity of Hematology." In the field of Hematology, basic science and clinical issues are strongly connected. New technology for medicine is applied soon after invented, and important scientific subjects have been found from patients with hematological diseases, proving the importance of "Bed to Bench, and Bench to Bed." For the future development of the field of Hematology, it is very important to involve diverse researchers in basic and clinical fields. Young doctors, senior doctors, those in basic and clinical fields, working in hospitals, academic institutions, and companies, are all welcome to the congress. Bertie acted as an invited speaker during a symposium entitled 'Evolving paradigm for blood cell differentiation'. |
| Year(s) Of Engagement Activity | 2020 |
| URL | http://www.jshem.or.jp/82/en/index.html |
| Description | Invited Speaker - University of Oslo Institute of Basic Medical Sciences Nansen Neuroscience Lecture 2020 - Thora Karadottir |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Nansen Neuroscience Lectures (NNL) honour Nansen's ground-breaking contribution to neuroscience, and since 10.10.10 the event is part of the Norwegian Academy of Science and Letters annual Nansen-celebration. Keeping the brain in shape is a prerequisite for good life, and particularly at old age, when age-associated diseases encroach upon us. Here we get updated on the current advances. Thora presented an invited lecture entitled "Myelin plasticity - a mechanism of learning and brain repair". |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.med.uio.no/imb/english/research/news-and-events/events/others/2020/nansen-neuroscience-l... |
| Description | John Van Geest Centre open day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Open day |
| Year(s) Of Engagement Activity | 2022 |
| Description | Keynote/Invited Speaker - 8th Annual German Stem Cell Network Conference - Bertie Göttgens |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The conference will cover novel and latest findings in stem cell biology. It continues to foster interactions between researchers working on different types of stem cells, including pluripotent stem cells, adult stem cells, stem cells in development, stem cells in aging and cancer stem cells. Bertie was one of five invited keynote speakers, and he presented a lecture entitled "Development and maintenance of the blood system." |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://gscn-conferences.org/previous-gscn-conferences/gscn-conference-2020/program-and-speakers |
| Description | Newmarket community concert |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Community fundraising concert in Suffolk organised by the family of an Institute Group Leader, including informal discussions with researchers and charity representation. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Organiser - Molecular Haemopoiesis 23 - Tony Green |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Molecular Haemopoiesis Meeting, which was initiated 23 years ago, is an annual gathering of the UK and European research communities studying blood cell development, with a particular focus on blood stem cell biology, developmental haematopoiesis, gene regulation and leukaemia. The meeting is organised by Professor Tony Green from the University of Cambridge, Professor Katrin Ottersbach from the University of Edinburgh, Professor Thomas Milne from the Weatherall Institute for Molecular Medicine in Oxford and Professor Dominique Bonnet from the Francis Crick Institute. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.stemcells.cam.ac.uk/whats-on/molecular-haemopoiesis-23 |
| Description | Organiser - Stem Cells UK 2020 - Tony Green |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This one day meeting aims to bring together stem cell researchers from across the UK to share research ideas, forge collaborations and meet friends old and new. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.stemcells.cam.ac.uk/whats-on/scuk |
| Description | PSC Support Ask The Expert Q&A - Fotis Sampaziotis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Online session with patient charity to discuss research and answer questions, livestreamed online. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.pscsupport.org.uk/dr-fotios-sampaziotis-recording-available/ |
| Description | Patient research day at JCBC |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A number of patients with IBD and their families visited the institute for discussion, tours and hands-on activities. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Patients with Parkinson's disease - patient led organisation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | OPen day |
| Year(s) Of Engagement Activity | 2022 |
| Description | Physical and Virtual Exhibit for Cambridge Rare Disease Network RAREfest 2020 - Giovanna Mantica |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | RAREfest 2020 is an award winning festival that is as unique as the patients it champions. Events and workshops feature the brightest minds in rare disease research, the innovators of life-changing technologies, the pioneers in rare disease medicine and the patients whose powerful voices must be heard. The Cambridge Stem Cell Institute hosts an exhibit called 'Cambridge Stem Cell Institute: Stem Cells and You' through which attendees can learn more about laboratory processes and aspirations. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.camraredisease.org/wp-content/uploads/2020/11/RAREfest20-Agenda.pdf |
| Description | Pint of Science |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Talk as part of established annual Cambridge Pint of Science series. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Plenary Speaker - CamBioScience Cerebral Organoids Course and 3D Cell Models Symposium - Joo-Hyeon Lee |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | We have developed a cerebral organoids course to empower scientists with this revolutionary technology. Using human pluripotent stem cells to create in vitro cerebral organoids allows the study of neural developmental mechanisms in human. They can also be used to understand the roots of human neurological diseases. Cerebral organoids can indeed be used in experiments where current in vitro methods are too simple. Therefore, they are more human applicable than rodent or other mammalian models. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.cambioscience.com/2019/11/13/cerebral-organoids-course-26-28-october-2020/ |
| Description | Poetry workshops with Parkinson's UK - with several CSCI scientists |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A series of poetry workshops with Parkinson's patients and stem cell researchers over six weeks, providing an opportunity to talk openly about, and write poetry reflecting, their lived experience of research and disease. Several CSCI Scientist were involved in this project: Shaline Fazal; Sophie Skidmore (Barker Group) Jaana Bagri (Huntly Group) Dominika Dziedzicka (Vallier Group) |
| Year(s) Of Engagement Activity | 2021 |
| Description | Profile for University of Cambridge's 'Women in STEM' Webpage Series - Oluwaseun Ogundele |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Oluwaseun Ogundele is a research assistant in the Hendrich Lab at the Wellcome-MRC Cambridge Stem Cell Institute. Here, she tells us about her work studying the body's master cells and their role in disease, meeting Nobel Prize winners, and how she's using social media to increase the visibility of women of colour working in STEM fields. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.cam.ac.uk/research/news/women-in-stem-oluwaseun-ogundele |
| Description | Responsive Research film You Tube videos as part of the Cambridge Science Festival |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Online video interview with the new Director of the Wellcome-MRC Cambridge Stem Cell Institute discussing the biomedical research landscape post-pandemic lockdowns, released as part of the Cambridge Festival programme as a follow-up to a 2020 video series. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://youtu.be/zrlOyBWif6k |
| Description | Sanjay Sinha - Face of BHF London Marathon |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Sanjay Sinha the Institutes Deputy Direct was the face of London Marathon this year. This led to numerous press interviews and advertising Billboards promoting him and his research. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://gosanjay.bhf.org.uk/ |
| Description | Stem Cell Institute - Technology & Innovation Forum (SCI-TIF) Launch |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Bertie Gottgens (Director of CSCI) organised the event to launch the new initiative which will pair industries with researchers at CSCI. Going forward, this launch event will become an annual Trainee Event, and will include other events like networking sessions, bespoke visits with industry, and workshops. The launch event included presentations by potential industry partners, PIs and Affiliates, and poster presentations from PhD and Postdocs. Following this event in November, six companies signed up to the membership as of January 2023. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.stemcells.cam.ac.uk/research/technology-innovation-forum |
| Description | Stem Cells 3 - CSCI were joint organisers of this public online event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Anthony Green (Director of CSCI) was a joint organiser of the event, working together with the Francis Crick Institute, the Centre for Regenerative Medicine, the DPAG Oxford and the London Stem Cell Network. Stem Cells UK 3 was one day event, the third annual event of its kind and will feature a full day of talks from leading stem cell experts, including from our own CSCI scientists, Maria Alcolea and Robin Franklin. |
| Year(s) Of Engagement Activity | 2019,2020,2021 |
| URL | https://www.stemcells.cam.ac.uk/events/stem-cells-uk-3 |
| Description | Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.cam.ac.uk/research/news/lab-grown-beating-heart-cells-identify-potential-drug-to-prevent... |
| Description | Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Story on Cambridge University Research page: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.cam.ac.uk/research/news/lab-grown-mini-bile-ducts-used-to-repair-human-livers-in-regener... |
| Description | Summit for Stem cell |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Webinar |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.summitforstemcell.org/cme-webinar-archive-photo-gallery/ |
| Description | Talking Together |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Series of six weekly telephone discussion groups on stem cell research delivered in partnership with Cambridge Older People's Enterprise's Talking Together programme. Discussion from each session was reflected in a pop-up exhibiion in the JCBC public space and on social media. Attendees reported an interest in visiting our laboratories in the future, and researchers were challenged to discuss their science without visual or digital aides. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Testimonial for NHS Blood and Transplant's 'R&D' Blog - Souradip Mookerjee |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | With this series of blogs, experts in haematology and stem cell biology provide insights into the research that NHS Blood and Transplant are working on to improve patient and donor care. Mr Souradip Mookerjee is an MB/PhD student in Dr Cedric Ghevaert's Lab at the University of Cambridge, working on the translational research of making platelets from stem cells. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.nhsbt.nhs.uk/research-and-development/rd-blog/modern-day-alchemy-in-vitro-derived-platel... |
| Description | The Perse School (Cambridge, UK) 'STEM: Stem Cell Special' School Visit, 28 February 2020 - Khalil Rawji and Celine Labouesse |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Celine Labouesse and Khalil Rawji participated in a discussion with Upper and Sixth Form students at The Perse School (Cambridge, UK) regarding Stem Cell Biology and careers in stem cell research. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.perse.co.uk/calendar/ |
| Description | Transeuro; the story so far, PI presenting results to patients in this trial |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Open day |
| Year(s) Of Engagement Activity | 2022 |
| Description | Trinity College, University of Cambridge 'Women in STEM' Virtual Event 2020 - Aditi Vedi |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Target group: Year 12 state schooled women and non-binary people studying the sciences to A-Level or equivalent standard. A virtual day in the life of a Cambridge undergraduate studying STEM: course overviews, mock supervisions and lectures, and the chance to speak with and ask questions to students and staff studying STEM subjects across the university. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.trin.cam.ac.uk/access/outreach-during-covid-19/ |
| Description | UFV Madrid visit to JCBC |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | A group of Spanish undergraduate biomedical students visiting Cambridge spent a morning at the institute for talks, tours and discussion with current and former students and staff. |
| Year(s) Of Engagement Activity | 2022 |
| Description | University of Cambridge Website and Newsletter article about the Clinical trial for new stem cell-based treatment for Parkinson's disease given go ahead |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | University of Cambridge Website and Newsletter article about the Clinical trial for new stem cell-based treatment for Parkinson's disease given go ahead. This led to further national and international press and media coverage. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.cam.ac.uk/research/news/clinical-trial-for-new-stem-cell-based-treatment-for-parkinsons-... |
| Description | University of Cambridge Website and Newsletter article about the First ever clinical trial of lab-grown red blood cell transfusion |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | University of Cambridge Website and Newsletter article about the First ever clinical trial of lab-grown red blood cell transfusion This led to further national and international press and media coverage. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.cam.ac.uk/research/news/first-ever-clinical-trial-underway-of-laboratory-grown-red-blood... |
| Description | Unknown Unknowns in conversation |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Panel discussion event held at JCBC and attended by staff, students, PE & creative practioners and blood cancer patients and their families to reflect on Anna Brownsted's 'Unknown unknowns' project delivered in 2020 in partnership with Blood Cancer UK and Kettle's Yard. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.stemcells.cam.ac.uk/events/unknown-unknowns-in-conversation |
| Description | Virtual Presentation Hosted by University of Cambridge's Lucy Cavendish College - Sanjay Sinha |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | About this Event: Dr Sinha will explain the power of stem cells and how they make huge differences in how we understand and treat a range of different heart and blood vessel diseases. He will also cover a wide range of topics from 'disease-in-a-dish' approaches to how to repair damaged hearts to testing new treatments for Covid-19. About the speaker: Dr Sanjay Sinha is a British Heart Foundation Senior Research Fellow and a Reader at the University of Cambridge. He completed medical training in Cambridge, followed by a PhD in Manchester. Dr Sinha then carried out post-doctoral studies in the USA before founding his group within the Wellcome-MRC Cambridge Stem Cell Institute. He has established new ways to use human stem cells to aid developmental studies and generate human models of vascular diseases, in particular Marfan syndrome. He is also investigating novel techniques to regenerate the damaged heart. Dr Sinha is also a Cardiologist and he combines his research work with clinical duties at Addenbrooke's Hospital, where he treats patients with a wide variety of cardiovascular diseases. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.eventbrite.co.uk/e/livefromlucy-with-dr-sanjay-sinha-tickets-129278574697# |
| Description | What would you become? (PE Seed Fund) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Co-creation of a new illustrated resource for primary school children and school libraries to highlight the breadth of career paths and roles which work together in research to answer scientific questions. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Whepstead community concert |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Community fundraising concert in Suffolk organised by the family of an Institute Group Leader, including informal discussions with researchers and charity representation. |
| Year(s) Of Engagement Activity | 2022 |